WO2021121420A1 - 苯并吡唑类化合物及其中间体、制备方法和应用 - Google Patents

苯并吡唑类化合物及其中间体、制备方法和应用 Download PDF

Info

Publication number
WO2021121420A1
WO2021121420A1 PCT/CN2020/137979 CN2020137979W WO2021121420A1 WO 2021121420 A1 WO2021121420 A1 WO 2021121420A1 CN 2020137979 W CN2020137979 W CN 2020137979W WO 2021121420 A1 WO2021121420 A1 WO 2021121420A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
heteroaryl
independently
ring
Prior art date
Application number
PCT/CN2020/137979
Other languages
English (en)
French (fr)
Inventor
蒋青
朱健
Original Assignee
江苏凯迪恩医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏凯迪恩医药科技有限公司 filed Critical 江苏凯迪恩医药科技有限公司
Publication of WO2021121420A1 publication Critical patent/WO2021121420A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to a benzopyrazole compound and its intermediate, preparation method and application.
  • Wnt signaling pathway plays a role in regulating the inducing interaction of growth and differentiation, and also plays a role in the homeostasis maintenance of tissue integrity after embryos. Wnt stabilizes cytoplasmic albumin, which stimulates the expression of genes including cmyc, c-jun, fra-1 and cyclin D1.
  • the dysregulation of Wnt signaling can lead to developmental defects and is involved in the occurrence of a variety of human cancers. It has been discovered that in the growing list of adult tissues including skin, blood, intestines, prostate, muscle and nervous system, the Wnt pathway is also involved in the maintenance of stem cells or progenitor cells.
  • MSC Mesenchymal stem cells
  • chondrocytes chondrocytes
  • osteoblasts chondrocytes
  • adipocytes adipocytes
  • mesenchymal stem cells include synovial mesenchymal stem cells, bone marrow mesenchymal stem cells, etc.
  • MSCs capable of multi-lineage differentiation (about 3% of the cells).
  • Wnt inhibitors can be used in stem cell research or treatment of any disease characterized by abnormal Wnt activation, and compounds that induce mesenchymal stem cells to treat and/or ameliorate related diseases and disorders.
  • the invention provides a benzopyrazole compound which is different from the prior art and its intermediate, preparation method and application.
  • the compounds of the present invention are used as Wnt inhibitors and mesenchymal stem cell inducers for the treatment and/or amelioration of related diseases and disorders.
  • the present invention provides a benzopyrazole compound as shown in formula I, its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, its metabolite, its stereoisomer, Its tautomers or prodrugs:
  • R 1a and R 1b are independently H or But R 1a and R 1b are not H at the same time;
  • the heteroatoms in the aromatic ring are independently selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4;
  • A is O or a C 1 ⁇ C 4 alkylene group
  • R 1b-1 and R 1b-2 are independently
  • Z and Z' are independently direct bonds, O, And when R 1a and R 1b and the carbon atoms to which they are connected together form a C 3 ⁇ C 10 heterocyclic ring substituted by R 1b-1 , Z and Z'are not straight bonds at the same time;
  • Q is a straight bond or a C 1 ⁇ C 4 alkylene group
  • R 1a-1 is independently C 6 ⁇ C 18 aryl, R 1a-1-1 substituted C 6 ⁇ C 18 aryl, C 3 ⁇ C 10 heteroaryl, or R 1a-1-2 substituted
  • the C 3 ⁇ C 10 heteroaryl group; the heteroatoms in the C 3 ⁇ C 10 heteroaryl group and the C 3 ⁇ C 10 heteroaryl group substituted by R 1a-1-2 are independently selected from N One or more of, O and S, the number of heteroatoms is 1 to 4;
  • R 1a-1-1 and R 1a-1-2 are independently halogen, C 1 ⁇ C 4 alkyl or cyano;
  • R 2 is a C 6 ⁇ C 18 aryl group, a C 6 ⁇ C 18 aryl group substituted by R 2-1 , a C 3 ⁇ C 10 heteroaryl group, or a C 3 ⁇ C 10 heteroaryl group substituted by R 2-2 , the hetero atom of C 3 ⁇ C 10 heteroaryl, and R 2-2 is a substituted C 3 ⁇ C 10 heteroaryl group is independently selected from N, O and S in one or more heteroatoms The number is 1 ⁇ 4;
  • R 2-1 and R 2-2 are independently Amino or
  • R 2-1-1 is a C 1 ⁇ C 4 alkyl group or a C 3 ⁇ C 6 cycloalkyl group
  • R 1b-1 , R 1b-2 , R 1a-1-1 , R 1a-1-2 , R 2-1 and R 2-2 are independently Is one or more; when said R 1b-1 , said R 1b-2 , R 1a-1-1 , R 1a-1-2 , said R 2-1 and said R 2 -2 plurality of independently said R 1b- 1, said R 1b-2, R 1a- 1-1, R 1a-1-2, R 2-1 and the said R 2-2 are independently the same or different.
  • R-substituted heterocyclic 1b-1 C 3 ⁇ C 10 is, C 3 ⁇ C 10 of Heteroaromatic ring or C 3 ⁇ C 10 heteroaromatic ring substituted by R 1b-2;
  • R 1b-1 and R 1b-2 are independently
  • Z is a straight key, O or
  • Z' is a straight key, And when R 1a and R 1b and the carbon atoms to which they are connected together form a C 3 ⁇ C 10 heterocyclic ring substituted by R 1b-1 , Z and Z'are not straight bonds at the same time;
  • Q is a straight bond or a C 1 ⁇ C 4 alkylene group
  • R 1a-1 is C 6 ⁇ C 18 aryl, R 1a-1-1 substituted C 6 ⁇ C 18 aryl, C 3 ⁇ C 10 heteroaryl, or R 1a-1-2 substituted C 3 ⁇ C 10 heteroaryl groups;
  • R 1a-1-1 is halogen
  • R 1a-1-2 is independently halogen, C 1 ⁇ C 4 alkyl or cyano
  • R 2 is a C 6 ⁇ C 18 aryl group, a C 6 ⁇ C 18 aryl group substituted by R 2-1 , a C 3 ⁇ C 10 heteroaryl group, or a C 3 ⁇ C 10 heteroaryl group substituted by R 2-2 ;
  • R 2-1 and R 2-2 are independently with
  • R 2-1-1 is a C 1 to C 4 alkyl group or a C 3 to C 6 cycloalkyl group.
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 ⁇ C 10 heterocyclic ring substituted by R 1b-1 , a C 3 ⁇ C 10 heteroaromatic ring or R 1b-2 substituted The C 3 ⁇ C 10 heteroaromatic ring;
  • R 1b-1 and R 1b-2 are independently
  • Z is a straight key, O or
  • Z' is a straight key, And when R 1a and R 1b and the carbon atoms to which they are connected together form a C 3 ⁇ C 10 heterocyclic ring substituted by R 1b-1 , Z and Z'are not straight bonds at the same time;
  • Q is a straight bond or a C 1 ⁇ C 4 alkylene group
  • R 1a-1 is a C 6 ⁇ C 18 aryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 1a-1-1;
  • R 1a-1-1 is halogen
  • R 1a-1-2 is independently halogen, C 1 ⁇ C 4 alkyl or cyano
  • R 2 is a C 3 ⁇ C 10 heteroaryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 2-2;
  • R 2-2 is independently
  • R 2-1-1 is a C 1 -C 4 alkyl group.
  • Z is a straight bond, O or
  • Z' is a straight bond
  • Q is a direct bond
  • R 1a-1 is independently a C 6 ⁇ C 18 aryl group, R 1a-1-1 substituted C 6 ⁇ C 18 aryl group, C 3 ⁇ C 10 heteroaryl group , R 1a-1-2 substituted C 3 ⁇ C 10 heteroaryl or C 3 ⁇ C 10 heterocycloalkyl; the C 3 ⁇ C 10 heteroaryl and R 1a-1-2 substituted
  • the heteroatoms in the C 3 ⁇ C 10 heteroaryl group are independently selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4; the C 3 ⁇ C 10 heterocyclic ring
  • the alkyl group is selected from one or more of N, O and S, and the number of heteroatoms is 1-4.
  • R 1a-1 is a C 6 to C 18 aryl group substituted by R 1a-1-1.
  • R 1a-1-2 is halogen or a C 1 to C 4 alkyl group.
  • the C 3 to C 10 heterocyclic ring substituted by R 1b-1 is wherein, the chemical bond between the two carbons marked with "*" is shared with the imidazole ring in formula I;
  • the C 3 ⁇ C 10 heteroaromatic ring substituted by R 1b-2 is wherein, the chemical bond between the two carbons marked with "*" is shared with the imidazole ring in formula I;
  • Z is O.
  • Z is
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 -C 10 heterocyclic ring substituted by R 1b-1.
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 to C 10 heteroaromatic ring or a C 3 to C 10 heteroaromatic ring substituted by R 1b-2;
  • R 1a-1 is a C 6 ⁇ C 18 aryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 1a-1-1;
  • R 1a-1-1 is halogen
  • Z is O
  • R 2 is a C 3 ⁇ C 10 heteroaryl substituted by R 2-2;
  • R 2-2 is independently
  • R 2-1-1 is a C 1 -C 4 alkyl group.
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 ⁇ C 10 heteroaromatic ring substituted by R 1b-2;
  • R 1a-1 is a C 6 ⁇ C 18 aryl group substituted by R 1a-1-1;
  • R 1a-1-1 is halogen
  • R 2 is a C 3 ⁇ C 10 heteroaryl substituted by R 2-2;
  • R 2-2 is independently
  • R 2-1-1 is a C 1 -C 4 alkyl group.
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 ⁇ C 10 heteroaromatic ring substituted by R 1b-2;
  • R 1a-1 is a C 6 ⁇ C 18 aryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 1a-1-1;
  • R 1a-1-1 is halogen
  • Z is a straight key or O
  • R 2 is a C 3 ⁇ C 10 heteroaryl substituted by R 2-2;
  • R 2-2 is independently
  • R 2-1-1 is a C 1 -C 4 alkyl group.
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 ⁇ C 10 heteroaromatic ring substituted by R 1b-2;
  • R 1a-1 is a C 6 ⁇ C 18 aryl group substituted by R 1a-1-1;
  • R 1a-1-1 is halogen
  • Z is a straight key or O
  • R 2 is a C 3 ⁇ C 10 heteroaryl substituted by R 2-2;
  • R 2-2 is independently
  • R 2-1-1 is a C 1 -C 4 alkyl group.
  • R 1a and R 1b together with the carbon atoms to which they are connected form a C 3 ⁇ C 10 heterocyclic ring substituted by R 1b-1;
  • R 1a-1 is a C 6 ⁇ C 18 aryl group substituted by R 1a-1-1;
  • R 1a-1-1 is independently halogen, C 1 ⁇ C 4 alkyl or cyano
  • Z is a straight key
  • R 2 is a C 3 ⁇ C 10 heteroaryl group.
  • the C terminal can be connected to A, and the Q terminal can be connected to R 1-a .
  • Z and Z' are preferably not direct bonds at the same time.
  • the C 1 ⁇ C 4 alkylene group may be methylene, ethylene, n-propylene, iso-propylene Propyl, n-butylene, Or tert-butylene, which may be methylene.
  • R 1a-1 to C 6 ⁇ C 18 aryl group or R 1a-1-1 unsubstituted C 6 ⁇ C 18 aryl group when said C 6 ⁇ C 18 aryl the The group may be a C 6 -C 14 aryl group (for example, a phenyl group, a naphthyl group, an anthryl group, or a phenanthryl group), and further may be a phenyl group.
  • R 1a-1 is R 1a-1-1-substituted aryl group of C 6 ⁇ C 18 when said R 1a-1-1 may be located at Z 'is ortho or Between bits.
  • R 1a-1 is R 1a-1-1 unsubstituted C 6 ⁇ C 18 aryl group when the number of the R 1a-1-1 may be one.
  • R 1a-1-1 when R 1a-1-1 is halogen, the halogen can be F, Cl, Br, or I, or F.
  • R 1a-1 is R 1a-1-1-substituted aryl group of C 6 ⁇ C 18 when said R 1a-1-1-substituted aryl group of C 6 ⁇ C 18 of It may be a C 6 -C 14 aryl group substituted by halogen, and further may be It can be further
  • R 1a-1 is a C 3 ⁇ C 10 heteroaryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 1a-1-2
  • the heteroatom in the heteroaryl group is N or S, and the number is one.
  • R 1a-1 is a C 3 ⁇ C 10 heteroaryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 1a-1-2
  • the heteroaryl group is a C 3 ⁇ C 5 heteroaryl group.
  • R 1a-1 is a C 3 ⁇ C 10 heteroaryl group
  • the C 3 ⁇ C 10 heteroaryl group may be a C 3 ⁇ C 5 heteroaryl group or a heteroatom It is N or S, the number is 1, further it can be pyridyl or thienyl, and further it can be It can be further
  • R 1a-1 is independently C 3 ⁇ C 10 heterocycloalkyl group
  • said C 3 ⁇ C 10 heterocycloalkyl group in the heteroatom is N, the number of 1.
  • R 1a-1 is independently a C 3 ⁇ C 10 heterocycloalkyl group
  • the C 3 ⁇ C 10 heterocycloalkyl group is a C 5 ⁇ C 6 heterocycloalkyl group. base.
  • R 1a-1 is independently a C 3 to C 10 heterocycloalkyl group
  • the C 3 to C 10 heterocycloalkyl group is a piperidinyl group
  • the hetero atom in the heterocyclic ring of ⁇ C 10 may be N, and the number is one.
  • the heterocyclic ring of ⁇ C 10 may be a heterocyclic ring of C 3 to C 5 , the heteroatom is N, the number of heteroatoms is 1, and further may be a piperidine ring (for example The N atom on the piperidinyl group is connected to Z', and the chemical bond between the two carbons marked with "*" is shared with the imidazole ring in formula I).
  • the carbon atom when R 1a and R 1b which they are attached form a heterocyclic-substituted C 3 ⁇ C 10 of R 1b-1 together, said R 1b-1 is a substituted C 3 ⁇ C 10
  • the heterocycle can be Can also be Among them, the chemical bond between the two carbons marked with "*" is shared with the imidazole ring in Formula I.
  • the carbon atom when R 1a and R 1b which they are attached form a C 3 ⁇ C 10 hetero aromatic ring or R 1b-2 heteroaromatic ring substituted C 3 ⁇ C 10 together the The heteroatom in the heteroaromatic ring of C 3 to C 10 may be N, and the number is one.
  • the carbon atom when R 1a and R 1b which they are attached form a C 3 ⁇ C 10 hetero aromatic ring or R 1b-2 heteroaromatic ring substituted C 3 ⁇ C 10 together
  • the The C 3 -C 10 heteroaromatic ring may be a C 3 -C 9 heteroaromatic ring.
  • the carbon atom when R 1a and R 1b which they are attached form a C 3 ⁇ C 10 hetero aromatic ring or R 1b-2 heteroaromatic ring substituted C 3 ⁇ C 10 together, the The heteroaromatic ring of C 3 to C 10 may be connected to Z'through a C atom.
  • the The C 3 ⁇ C 10 heteroaromatic ring can be a C 3 ⁇ C 9 heteroaromatic ring, the heteroatom is N, the number of heteroatoms is 1, and further can be a pyridine ring or a quinoline ring (for example That is, the pyridyl group is connected to Z'through the C atom, and the chemical bond between the two carbons marked with "*" is shared with the imidazole ring in formula I).
  • the heteroaromatic ring of 10 can be Can also be Among them, the chemical bond between the two carbons marked with "*" is shared with the imidazole ring in Formula I.
  • R 2 is a C 3 ⁇ C 10 heteroaryl group or a C 3 ⁇ C 10 heteroaryl group substituted by R 2-2
  • the C 3 ⁇ C 10 heteroaryl group is The heteroatom of can be N, and the number is one.
  • the C 3 ⁇ C 10 heteroaryl group may be It is a C 3 ⁇ C 5 heteroaryl group.
  • the C 3 ⁇ C 10 heteroaryl group may be It is a C 3 -C 5 heteroaryl group, the heteroatom is N, the number is 1, and further is a pyridyl group, for example
  • R 2 when R 2 is substituted with 2-2 R C 3 ⁇ C 10 heteroaryl group, said R may be a number of 2-2.
  • R 2-2 is When the R 2-1-1 is a C 1 to C 4 alkyl group, the C 1 to C 4 alkyl group can be methyl, ethyl, n-propyl, isopropyl, n-butyl , Or tert-butyl, which can be ethyl or Can also be
  • R 2 is R 2-2 substituted heteroaryl C 3 ⁇ C 10 aryl group
  • said R 2-2 is a substituted heteroaryl C 3 ⁇ C 10 aryl group
  • the benzopyrazole compound represented by formula I is any of the following compounds:
  • the present invention also provides a benzopyrazole compound as shown in formula I, its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, its metabolite, its stereoisomer ,
  • the preparation method of its tautomer or its prodrug which comprises the following steps: in a solvent, in the presence of a deprotection reagent, the compound represented by formula II is subjected to the deprotection reaction of the following formula to obtain the The benzopyrazole compound shown in formula I is sufficient;
  • R 3 is an amino protecting group
  • R 1a , R 1b , R 2 and Z have the same definitions as described above.
  • the conditions and operations of the deprotection reaction can be conventional conditions and operations in the art, and the following conditions and operations are particularly preferred in the present invention.
  • R 3 when R 3 is an amino protecting group, the amino protecting group can be a conventional amino protecting group in the art, preferably tetrahydropyran (THP).
  • THP tetrahydropyran
  • the solvent can be a conventional solvent in the field, preferably a chlorinated hydrocarbon solvent, and more preferably dichloromethane.
  • the deprotection reagent can be a conventional deprotection reagent in the art, preferably an organosilane compound (for example, triethyl silane) and an organic acid (for example, trifluoroacetic acid).
  • organosilane compound for example, triethyl silane
  • organic acid for example, trifluoroacetic acid.
  • the molar ratio of the organic silane compound to the organic acid may be 1:5 to 1:20, such as 1:12.
  • the temperature of the deprotection reaction may be 10-40°C, such as room temperature.
  • the progress of the deprotection reaction can be monitored by conventional methods in the art (for example, TLC, HPLC, nuclear magnetism), and the reaction end point is usually that the compound represented by formula II no longer reacts or disappears.
  • the time for the deprotection reaction can be 10-18 hours, such as overnight.
  • post-treatment includes the following steps: concentrating the reaction solution after the reaction, depositing solids, and column chromatography.
  • the conditions and operations of the concentration can be conventional conditions and operations in the art.
  • the conditions and operations for the precipitation of solids can all adopt conventional conditions and operations in the art.
  • the reagent used for the solid precipitation can be an inorganic base, and ammonia water is more preferred (for example, the concentration of ammonia water is 5 mol/L).
  • the conditions and operations of the column chromatography can adopt the conventional conditions and operations in the art.
  • the eluent used in the column chromatography can be alcohol reagents and chlorinated hydrocarbon reagents, and further can be dichloromethane and methanol (for example, the volume ratio of dichloromethane and methanol is 20:1-10:1).
  • the present invention also provides a compound represented by formula II,
  • R 3 is an amino protecting group
  • R 1a , R 1b , R 2 and Z have the same definitions as described above.
  • the compound represented by formula II is preferably any one of the following compounds:
  • the present invention also provides a method for preparing the compound represented by formula II, which comprises the following steps: in a solvent, in the presence of a cyclization reagent, the compound represented by formula III and the compound represented by formula IV are combined The compound of is subjected to the following cyclization reaction to obtain the compound represented by formula II;
  • R 1a , R 1b , R 2 , R 3 and Z are the same as described above.
  • the conditions and operations of the cyclization reaction can be conventional conditions and operations in the art, and the following conditions and operations are particularly preferred in the present invention.
  • the solvent may be a conventional solvent in the field, preferably a pyrrolidone solvent, and more preferably N-methylpyrrolidone.
  • the cyclization reagent can be a conventional reagent in the art, preferably an alkali metal metabisulfite (such as sodium metabisulfite).
  • the molar ratio of the cyclization reagent to the compound represented by formula III may be 1:1.1 to 1.2:1, such as 1.2:1.
  • the temperature of the cyclization reaction may be 100-140°C, for example 100°C.
  • the progress of the cyclization reaction can be monitored by conventional methods in the art (for example, TLC, HPLC, nuclear magnetism), and the reaction end point is usually that the compound represented by formula II no longer reacts or disappears.
  • the cyclization protection reaction time can be 10-18 hours, such as overnight.
  • post-treatment includes the following steps: cooling the reaction liquid after the reaction to room temperature, and depositing a solid.
  • the conditions and operations for the precipitation of solids can all adopt conventional conditions and operations in the art.
  • the reagent used to precipitate solids is water.
  • the present invention also provides a pharmaceutical composition, which comprises a benzopyrazole compound as shown in formula I, its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, and its metabolite , Its stereoisomers, its tautomers or its prodrugs, and pharmaceutical excipients.
  • the present invention also provides a benzopyrazole compound as shown in formula I, its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, its metabolite, its stereoisomer , The application of its tautomer or its prodrug, or the above-mentioned pharmaceutical composition in the preparation of an inducer.
  • the above-mentioned inducer can induce proteoglycan (Aggrecan), type II collagen (Collagen II), sox9, type I collagen (collagen I), type X collagen (collagen X), osteogenic transcription genes ( Increased expression of one or more genes in RUNX2) or alkaline phosphatase (ALP).
  • Aggrecan proteoglycan
  • type II collagen Collagen II
  • sox9 type I collagen
  • type X collagen type X collagen
  • osteogenic transcription genes Increased expression of one or more genes in RUNX2
  • ALP alkaline phosphatase
  • the inducer can differentiate synovial stem cells into chondrogenic and/or osteoblasts.
  • the inducer can also be used for bone building agents, or, treatment or prevention of periodontal disease, arthritis (e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic joints) Inflammation, osteoarthritis), joint damage, cartilage repair, bone regeneration, osteoporosis, osteopenia, spinal fusion, periodontal disease, and bone tumors.
  • arthritis e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic joints
  • Inflammation e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic joints
  • Inflammation e.g. rheumatoid arthritis, psoriatic arthritis, an
  • the bone building agent can enhance fracture recovery and stimulate bone growth at the location of bone transplantation, joint transplantation or tooth transplantation.
  • the present invention also provides a benzopyrazole compound as shown in formula I, its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, its metabolite, its stereoisomer
  • a benzopyrazole compound as shown in formula I its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, its metabolite, its stereoisomer
  • the diseases related to one or more proteins in the Wnt pathway may be cancer, diseases related to abnormal angiogenesis, diseases related to cell proliferation and cell cycle, or diseases related to Wnt signaling components.
  • the cancer may be one or more of colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, bone cancer and leukemia.
  • the diseases related to abnormal angiogenesis may be hematopoietic tumors of the lymphoid lineage, hematopoietic tumors of the bone marrow lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system and melanoma, seminoma, Kaposi's sarcoma, benign prostatic hyperplasia, familial adenomatous polyposis, neurofibroma, atherosclerosis, arthritis, nephritis, restenosis after angioplasty or vascular surgery, inflammatory bowel disease, transplant rejection, endotoxin One or more of shock and fungal infection.
  • the disease caused by the variation or imbalance of one or more of the Wnt signal transduction components can be colonic polyposis, osteoporosis, pseudoglioma syndrome, familial exudative vitreous Retinopathy, retinal angiogenesis, early coronary heart disease, congenital amputation syndrome, accessory mesonephros reversion and virilization, SERKAL syndrome, type 2 diabetes, Fuhrman syndrome, AARRS short limb syndrome, dental nail Skin dysplasia, obesity, split hand/foot deformity, caudal duplication syndrome, congenital absence of teeth, Wilms tumor, skeletal dysplasia, focal skin hypoplasia, neural tube defect, alpha thalassemia syndrome, fragility One or more of X syndrome, ICF syndrome, Angelman's syndrome, Pa-Wei syndrome, Bay-Whis syndrome, Norrie's disease and Rett syndrome.
  • the present invention also provides a benzopyrazole compound as shown in formula I, its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorph, its metabolite, its stereoisomer , Its tautomer or its prodrug, or the application of the above-mentioned pharmaceutical composition in the preparation of medicines.
  • the drug can differentiate synovial stem cells into chondrogenic and/or osteoblasts.
  • the drug can also be used for bone building agents, or, treatment or prevention of periodontal disease, arthritis (e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis) , Osteoarthritis), joint damage, cartilage repair, bone regeneration, osteoporosis, osteopenia, spinal fusion, periodontal disease and bone tumors.
  • arthritis e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis
  • Osteoarthritis e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis
  • Osteoarthritis e.g. rheumatoid arthritis, psoriatic
  • the bone building agent can enhance fracture recovery and stimulate bone growth at the location of bone transplantation, joint transplantation or tooth transplantation.
  • the drugs can be used to treat and/or prevent diseases related to one or more proteins in the Wnt pathway.
  • the disease is the same as the previous one.
  • the drugs can be used to treat and/or prevent cancer, diseases related to abnormal angiogenesis, diseases related to cell proliferation and cell cycle, or one of the Wnt signal transduction components. Diseases caused by one or more kinds of mutations or disorders.
  • the cancer the disease related to abnormal angiogenesis, the disease related to cell proliferation and cell cycle, or the mutation or disorder of one or more of the Wnt signaling components
  • the diseases caused are the same as mentioned above.
  • the present invention also provides a method for inducing differentiation of synovial mesenchymal stem cells into chondroblasts, inducing differentiation of osteoblasts, or inhibiting the formation of osteoclasts, which comprises administering to a subject (preferably giving the subject a therapeutically effective amount)
  • a subject preferably giving the subject a therapeutically effective amount
  • the above-mentioned benzopyrazole compound as shown in formula I its pharmaceutically acceptable salt, its hydrate, its solvate, its polymorphic form, its metabolite, its stereoisomer, its Tautomers or prodrugs thereof, or the above-mentioned pharmaceutical compositions.
  • the subject can be a mammal, and further can be a human.
  • the chondrogenic cells and/or osteoblasts are derived from the differentiation of synovial mesenchymal stem cells.
  • MSCs are pluripotent stem cells that can differentiate into several different types of cells, including but not limited to osteoblasts, chondrocytes, and adipocytes. Differentiation is the process of forming specialized cell types from less specialized cell types, such as chondrocytes from MSCs.
  • the chondrocytes are produced or maintained by the expression of one or more genes among proteoglycan (Aggrecan), type II collagen (Collagen II) and sox9.
  • Said promotion of osteogenic differentiation and inhibition of osteoclast formation are composed of one of type I collagen (collagen I), type X collagen (collagen X), osteogenic transcription gene (RUNX2) or alkaline phosphatase (ALP) Or the expression of multiple genes is produced or maintained.
  • the present invention also provides a method for treating or preventing diseases related to one or more proteins in the Wnt pathway, which comprises administering to a subject (preferably to the subject a therapeutically effective amount) in need of treatment, as described in Formula I above
  • a subject preferably to the subject a therapeutically effective amount
  • the benzopyrazole compounds shown their pharmaceutically acceptable salts, their hydrates, their solvates, their polymorphs, their metabolites, their stereoisomers, their tautomers or their precursors Medicine, or the above-mentioned pharmaceutical composition.
  • pharmaceutically acceptable means that salts, solvents, excipients, etc. are generally non-toxic, safe, and suitable for use by patients.
  • the "patient” is preferably a mammal, more preferably a human.
  • pharmaceutically acceptable salt refers to a salt prepared from a compound of the present invention with a relatively non-toxic, pharmaceutically acceptable acid or base.
  • the compound of the present invention contains a relatively acidic functional group, it can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salt, sodium salt, potassium salt, calcium salt, aluminum salt, magnesium salt, zinc salt, bismuth salt, ammonium salt, and diethanolamine salt.
  • the acid addition can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent.
  • a pharmaceutically acceptable acid include inorganic acids, and the inorganic acids include, but are not limited to: hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, phosphoric acid, phosphorous acid, sulfuric acid, and the like.
  • the pharmaceutically acceptable acids include organic acids, including but not limited to: acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid , Fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, acid citric acid, oleic acid , Tannic acid, pantothenic acid, hydrogen tartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e.
  • crystal form means that the ions or molecules are arranged strictly and periodically in a three-dimensional space in a certain way, and have the regularity of periodic recurrence at a certain distance; due to the above-mentioned periodic arrangement, there may be multiple Crystal form, that is, polymorphism.
  • compound and “pharmaceutically acceptable salt” may exist in the form of a single stereoisomer or a mixture thereof (for example, a racemate) if there are stereoisomers.
  • stereoisomer refers to cis-trans isomers or optical isomers. These stereoisomers can be separated, purified and enriched by asymmetric synthesis methods or chiral separation methods (including but not limited to thin layer chromatography, rotation chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and can also be obtained by It can be obtained by chiral resolution by forming bonds with other chiral compounds (chemical bonding, etc.) or salting (physical bonding, etc.).
  • single stereoisomer means that the mass content of one stereoisomer of the compound of the present invention relative to all stereoisomers of the compound is not less than 95%.
  • compound and “pharmaceutically acceptable salt” may exist in the form of a single tautomer or a mixture thereof if tautomers exist, preferably in the form of relatively stable tautomers.
  • the body-based form exists.
  • the atoms in the terms “compound” and “pharmaceutically acceptable salt” may exist in their natural abundance or non-natural abundance. Taking the hydrogen atom as an example, the form of its natural abundance means that about 99.995% of it is protium and about 0.015% is deuterium; the form of its unnatural abundance means that about 95% of it is deuterium. That is, one or more atoms in the terms “compound” and “pharmaceutically acceptable salt” may be atoms existing in a form of unnatural abundance.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • alkyl refers to a straight or branched chain alkyl group having the specified number of carbon atoms.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl and It is similar to an alkyl group.
  • alkoxy refers to the group -OR X , where R X is an alkyl group as defined above.
  • cycloalkyl refers to a monovalent saturated cyclic alkyl group, preferably a monovalent saturated cyclic alkyl group having 3-7 ring carbon atoms, more preferably 3-6 carbon atoms, such as cyclopropyl, cyclobutyl Group, cyclopentyl or cyclohexyl.
  • heterocycloalkyl refers to a saturated monocyclic group with heteroatoms, preferably a 3-7 membered saturated ring containing 1, 2 or 3 ring heteroatoms independently selected from N, O and S Single ring.
  • heterocycloalkyl groups are: pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridyl, tetrahydropyrrolyl, azetidinyl, thiazolidinyl, oxazolidinyl , Piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazacycloheptanyl, oxazepanyl, etc.
  • Preferred heterocyclic groups are morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, thiomorpholin-4-
  • aryl refers to a group having a 4n+2 aromatic ring system (e.g., having 6, 10, or 14 shared p electrons in a cyclic array). Examples of the aforementioned aryl unit include phenyl, naphthyl, phenanthryl, or anthracenyl.
  • heteroaryl refers to an aromatic group containing heteroatoms, preferably containing 1, 2, or 3 aromatic 5-6 membered monocyclic rings or 9-10 membered bicyclic rings independently selected from nitrogen, oxygen and sulfur ,
  • heteroaryl refers to an aromatic group containing heteroatoms, preferably containing 1, 2, or 3 aromatic 5-6 membered monocyclic rings or 9-10 membered bicyclic rings independently selected from nitrogen, oxygen and sulfur ,
  • furyl pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, diazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazole Group, thiazolyl, isothiazolyl, thiadiazolyl, benzimidazolyl, indolyl, indazolyl, benzothiazolyl, benzisothiazolyl,
  • pharmaceutical excipients refers to excipients and additives used in the production of drugs and formulating prescriptions, and are all substances contained in pharmaceutical preparations except for active ingredients. Please refer to the fourth part of the Pharmacopoeia of the People's Republic of China (2015 Edition), or Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009 Sixth Edition).
  • terapéuticaally effective amount refers to a dose that produces a therapeutic effect.
  • the exact dose will depend on the purpose of the treatment and can be determined by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Pharmaceutical, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Domain Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
  • the reagents and raw materials used in the present invention are all commercially available.
  • the positive and progressive effect of the present invention is that the benzopyrazole compounds of the present invention are effective against one or more of proteoglycan, type II collagen, sox9, type I collagen, type X collagen, osteogenic transcription genes and alkaline phosphatase.
  • the species has a good inducing effect, which can then be used to treat and/or improve related diseases and disorders.
  • the first step 3-bromo-5-nitropyridin-4-amine
  • the third step 5-(3-fluorophenyl)pyridine-3,4-diamine
  • NIS 9 g, 40.2 mmol
  • DCM solution containing compound 2 8.3 g, 33.5 mmol
  • the reaction was stirred at room temperature for 3 hours.
  • the organic phase was washed with water and sodium thiosulfate solution respectively.
  • PTSA 0.53 g, 2.81 mmol
  • tetrahydrofuran containing compound 3 10.5 g, 28.1 mmol
  • DHP 4.7 g, 56.1 mmol
  • the reaction solution was stirred at room temperature for 3 hours.
  • acetyl chloride (1.9 g, 24.4 mmol) was added dropwise to a 100 mL dichloromethane solution containing compound 6 (6.8 g, 18.7 mmol) and TEA (5.69 g, 56.4 mmol).
  • the solution was reacted at room temperature for 2 hours. It was quenched with NaHCO3 aqueous solution, the solution was extracted with ethyl acetate, and the organic phase was spin-dried.
  • TBAF 8.8 g, 33.6 mmol
  • compound 7 6.8 g, 16.8 mmol
  • the solution was stirred at room temperature for 16 hours.
  • the solvent was spin-dried, the residue was diluted with ethyl acetate, and then washed three times with water.
  • the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain a crude product of 5.3 g of white solid, which was directly used in the next reaction.
  • MnO 2 (0.7 g, 8.1 mmol) was added to 20 mL of ethyl acetate solution containing compound 12 (1.6 g, 4.05 mmol). The solution was reacted at room temperature for 2 hours. Filter through diatomaceous earth, spin the filtrate to dryness, and purify the crude product with 1.1 g light yellow solid by a reverse phase preparation column, with a yield of 69%.
  • MnO 2 (0.7 g, 8.1 mmol) was added to 20 mL of ethyl acetate solution containing compound 14 (1.6 g, 4.05 mmol). The solution was reacted at room temperature for 2 hours. After filtering through diatomaceous earth, the filtrate was spin-dried, and the crude product was purified with a reverse phase preparation column to obtain 1.1 g of white solid with a yield of 89%.
  • PdCl 2 was added to a mixed solution of acetonitrile (300 mL) and water (60 mL) containing compound 2 (15.6 g, 50.5 mmol), compound 3 (10.1 g, 45.9 mmol) and Na 2 CO 3 (14.46 g, 137.7 mmol) (dppf) (1.68 g, 2.3 mmol).
  • the solution was heated to 100°C under nitrogen protection, and reacted for 3 hours. Cool to room temperature, filter with celite, spin-dry the filtrate, and use the residue directly in the next step without further purification. 18.6 g of gray-brown solid was obtained.
  • compound 5 (9.01 g, 75.09 mmol) was added dropwise to a DCM (500 mL) solution containing compound 4 (18.6 g, 57.76 mmol) and TEA (17.05 g, 173.3 mmol).
  • the reaction solution was raised to room temperature and stirred at room temperature for 3 hours.
  • the reaction solution was poured into 500 mL of water.
  • the solution was extracted twice with DCM, the organic phases were combined, dried, the solvent was removed, and purified by reverse-phase flash chromatography to obtain 10.3 g of yellow solid with a yield of 48%.
  • HATU 4.3 g, 11.3 mmol
  • DIPEA 3.36 g, 26.1 mmol
  • the solution was raised to room temperature and reacted for 2 hours.
  • the reaction solution was poured into 100 mL of water, and the solution was extracted twice with ethyl acetate.
  • the first step 3-bromo-5-nitropyridin-4-amine
  • Step 2 N-(4,5-diaminopyridin-3-yl)pyridine amide
  • the first step 5-nitropyridine-3,4-diamine
  • R 2q THP: Intermediate 3-2 was added to a 250mL three-necked flask, tetrahydrofuran (180mL), p-toluenesulfonic acid (0.690.1eq) were added, 3,4-dihydropyran (6.72g) was added dropwise at room temperature , 2eq) and react at 40°C for 8h. Subsequently, the solvent was evaporated under reduced pressure, and the crude intermediate 3-3 (THP) was obtained by purification by silica gel column chromatography. After beating with PE, a white solid was obtained with a yield of 32%.
  • Intermediate 3-4 (THP, 1.07g, 3mmol), intermediate 2-2 (isovaleric acid, 0.93g, 1.2eq), sodium carbonate (0.95g, 3eq), Pd(dppf)Cl 2 (0.1g ,0.05eq), dioxane (9mL), and water (1.5mL) were added to a 50mL single-necked flask, the air was replaced by nitrogen, and the temperature was raised to reflux for 8h. After cooling, suction filtration, spin-drying, and purification by silica gel column chromatography to obtain Intermediate 4-1, a yellow oil, with a yield of 69%. The operations of other substituents are the same as above.
  • Boc-piperidone (10g, 50.19mmol, 1eq) was dissolved in 100mL ethanol, hydroxylamine hydrochloride (6.97g, 100.38mmol, 2eq) and sodium acetate (8.23g, 100.38mmol, 2eq) were added, and the reaction was refluxed for 8 hours.
  • Dissolve 3-1 (9g, 42mmol, 1eq) in 90mL of dichloromethane, add triethylamine (4.67g, 46.2mmol, 1.1eq), cool to 0°C, add p-toluenesulfonyl chloride (7.95g, 46.2mmol , 1.1eq), react at room temperature for 8 hours.
  • Post-treatment add saturated brine to the reaction solution, separate the liquids, and spin-dry the organic phase to obtain a white solid with a yield of 71%
  • Post-treatment suction filtration, discard the filter cake, and spin-dry the filtrate to obtain a pale yellow oil without purification treatment.
  • Post-treatment add ice water to the reaction solution, solids will precipitate out, filter with suction, and dry the filter cake to obtain a yellow solid with a yield of 86%.
  • Post-treatment the reaction solution was spin-dried, ethyl acetate was added, and the organic phase was spin-dried after washing with saturated brine to obtain a pale yellow solid without purification treatment.
  • Post-treatment suction filtration and drying of the filter cake to obtain a pale yellow solid without purification treatment.
  • Post-treatment add 10 ml of ice water to the reaction solution, extract with 30 ml of ethyl acetate, combine the organic phases, and concentrate to obtain a yellow oil without purification treatment.
  • Post-treatment add 10 ml of ice water to the reaction solution, extract with 30 ml of ethyl acetate, combine the organic phases, and concentrate to obtain a yellow oil without purification treatment.
  • Post-treatment add 10 ml of ice water to the reaction solution, extract with 30 ml of ethyl acetate, combine the organic phases, and concentrate to obtain a yellow oil without purification treatment.
  • Post-treatment add 10 ml of ice water to the reaction solution, extract with 30 ml of ethyl acetate, combine the organic phases, and concentrate to obtain a yellow oil without purification treatment.
  • SMSC Human-derived synovial mesenchymal stem cells
  • cartilage genes proteoglycan Aggrecan
  • collagen II Collagen II
  • sox9 osteogenic genes
  • osteogenic genes collagen I (collagen I), collagen X (collagen X), osteogenic transcription genes (RUNX2)
  • alkaline The relative expression level of genes such as phosphatase (ALP) in the cell.
  • the relative expression level was detected using the LightCycler 480 II system (Roche).
  • the vehicle (DMSO) was used as a control to determine the basic level of chondrogenic osteoblast differentiation.
  • the target genes to be tested in this experiment are Aggrecan, Collagen II, sox9, Collagen I, Collagen X, RUNX2, and ALP genes, and the internal reference gene is GAPDH.
  • the three genes of Aggrecan, Collagen II, and sox9 are chondrogenic genes, and collagen I (collagen I), collagen X (collagen X), osteogenic transcription genes (RUNX2), and alkaline phosphatase (ALP) are osteogenic genes.
  • the gene, sox2 is a transcription factor and a hallmark of induced stem cells. The specific results are shown in Table 1:
  • a ⁇ D represent different activity levels respectively, see Table 2 below for details:
  • synovial mesenchymal stem cells differentiate into chondrogenic and/or osteoblasts, which can be used to treat or prevent arthritis, joint damage, osteogenic regeneration, osteoporosis, and bone One or more diseases in the tumor.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种苯并吡唑类化合物及其中间体、制备方法和应用。苯并吡唑类化合物如式I所示。式I所示化合物作为Wnt途径中一种或多种蛋白的抑制剂，以及对蛋白多糖、Ⅱ型胶原、sox9、Ⅰ型胶原、Ⅹ型胶原、成骨转录基因和碱性磷酸酶中的一种或多种具有较好的诱导作用，进而可以用来治疗和/或预防相关疾病。

Description

苯并吡唑类化合物及其中间体、制备方法和应用
本申请要求申请日为2019/12/20的中国专利申请PCT/CN2019/126826的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明涉及一种苯并吡唑类化合物及其中间体、制备方法和应用。
背景技术
在脊椎动物和无脊椎动物发育过程中，信号传导分子的Wnt家族的成员介导许多短程和长程模式化过程。己知Wnt信号传导途径在调节生长和分化的诱导相互作用中有作用，并且在胚胎后组织完整性的内稳态维持中也起作用。Wnt稳定胞质白连锁蛋白，其剌激包括cmyc、c-jun、fra-l和细胞周期蛋白Dl在内的基因的表达。
此外，Wnt信号传导的失调可导致发育缺陷，且在多种人类癌症的发生中有关。己发现在包括皮肤、血液、肠道、前列腺、肌肉和神经系统的不断增长的成人组织列表中，Wnt途径还与干细胞或祖细胞的维护有关。
存在于骨髓和大多数成体组织中的间充质干细胞(MSC)能够自我更新并分化成为多种细胞谱系，包括软骨细胞、成骨细胞和脂肪细胞(Pittenger,M.F.等人，Science,1999.284(5411):p.143-7)，其中间充质干细胞包括滑膜间充质干细胞、骨髓间充质干细胞等，研究发现，成体关节软骨含有能够多谱系分化的MSC(细胞的大约3％)。鉴于间充质干细胞以上特征，如何实现间充质干细胞的成骨、成软骨定向分化，为治疗相关疾病提供依据及思路，则成为了大家关注的焦点。
因此，探索Wnt抑制剂可用于干细胞研究或治疗以Wnt异常激活为特征的任何疾病、以及诱导充质干细胞用于治疗和/或改善相关的疾病和病症的化合物意义重大。
发明内容
本发明提供了一种与现有技术不同的苯并吡唑类化合物及其中间体、制备方法和应用。本发明的化合物作为Wnt抑制剂以及间充质干细胞诱导剂，用于治疗和/或改善相关的疾病和病症。
本发明提供了一种如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药：
Figure PCTCN2020137979-appb-000001
其中，R 1a和R 1b独立地为H或
Figure PCTCN2020137979-appb-000002
但R 1a和R 1b不同时为H；
或者，R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
所述的C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环、R 1b-2取代的C 3～C 10的杂芳环中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
A为O或C 1～C 4的亚烷基；
R 1b-1和R 1b-2独立地为
Figure PCTCN2020137979-appb-000003
Z和Z'独立地为直键、O、
Figure PCTCN2020137979-appb-000004
且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
Q为直键或C 1～C 4的亚烷基；
R 1a-1独立地为C 6～C 18的芳基、R 1a-1-1取代的C 6～C 18的芳基、C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基；所述的C 3～C 10的杂芳基和R 1a-1-2取代的C 3～C 10的杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
R 1a-1-1和R 1a-1-2独立地为卤素、C 1～C 4的烷基或氰基；
R 2为C 6～C 18的芳基、R 2-1取代的C 6～C 18的芳基、C 3～C 10杂芳基或R 2-2取代的C 3～C 10杂芳基，所述的C 3～C 10杂芳基和R 2-2取代的C 3～C 10杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
R 2-1和R 2-2独立地为
Figure PCTCN2020137979-appb-000005
氨基或
Figure PCTCN2020137979-appb-000006
R 2-1-1为C 1～C 4的烷基或C 3～C 6的环烷基；
所述的R 1b-1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2的个数独立地为一个或多个；当所述的R 1b-1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2独立地为多个时，所述的R 1b- 1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2独立地相同或不同。
本发明中，所述的如式I所示的苯并吡唑类化合物中某些取代基的定义可如下所述，未提及的取代基的定义均如上任一方案所述。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
R 1b-1和R 1b-2独立地为
Figure PCTCN2020137979-appb-000007
Z为直键、O或
Figure PCTCN2020137979-appb-000008
Z'为直键、
Figure PCTCN2020137979-appb-000009
且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
Q为直键或C 1～C 4的亚烷基；
R 1a-1为C 6～C 18的芳基、R 1a-1-1取代的C 6～C 18的芳基、C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基；
R 1a-1-1为卤素；
R 1a-1-2独立地为卤素、C 1～C 4的烷基或氰基；
R 2为C 6～C 18的芳基、R 2-1取代的C 6～C 18的芳基、C 3～C 10杂芳基或R 2-2取代的C 3～C 10杂芳基；
R 2-1和R 2-2独立地为
Figure PCTCN2020137979-appb-000010
和
R 2-1-1为C 1～C 4的烷基或C 3～C 6的环烷基。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
R 1b-1和R 1b-2独立地为
Figure PCTCN2020137979-appb-000011
Z为直键、O或
Figure PCTCN2020137979-appb-000012
Z'为直键、
Figure PCTCN2020137979-appb-000013
且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
Q为直键或C 1～C 4的亚烷基；
R 1a-1为R 1a-1-1取代的C 6～C 18的芳基或C 3～C 10的杂芳基；
R 1a-1-1为卤素；
R 1a-1-2独立地为卤素、C 1～C 4的烷基或氰基；
R 2为C 3～C 10杂芳基或R 2-2取代的C 3～C 10杂芳基；
R 2-2独立地为
Figure PCTCN2020137979-appb-000014
和R 2-1-1为C 1～C 4的烷基。
在某一优选实施方式中，Z为直键、O或
Figure PCTCN2020137979-appb-000015
在某一优选实施方式中，Z'为直键、
Figure PCTCN2020137979-appb-000016
优选
Figure PCTCN2020137979-appb-000017
在某一优选实施方式中，Q为直键。
在某一优选实施方式中，R 1a-1独立地为C 6～C 18的芳基、R 1a-1-1取代的C 6～C 18的芳基、C 3～C 10的杂芳基、R 1a-1-2取代的C 3～C 10的杂芳基或C 3～C 10的杂环烷基；所述的C 3～C 10的杂芳基和R 1a-1-2取代的C 3～C 10的杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；所述的C 3～C 10的杂环烷基中选自N、O和S中的一种或多种，杂原子数为1～4。
在某一优选实施方式中，R 1a-1为R 1a-1-1取代的C 6～C 18的芳基。
在某一优选实施方式中，R 1a-1-2为卤素或C 1～C 4的烷基。
在某一优选实施方式中，所述的R 1b-1取代的C 3～C 10的杂环为
Figure PCTCN2020137979-appb-000018
Figure PCTCN2020137979-appb-000019
其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用；
和，
Figure PCTCN2020137979-appb-000020
为
Figure PCTCN2020137979-appb-000021
在某一优选实施方式中，所述的R 1b-2取代的C 3～C 10的杂芳环为
Figure PCTCN2020137979-appb-000022
Figure PCTCN2020137979-appb-000023
其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用；
和，
Figure PCTCN2020137979-appb-000024
为
Figure PCTCN2020137979-appb-000025
Figure PCTCN2020137979-appb-000026
在某一优选实施方式中，Z为O。
在某一优选实施方式中，Z为
Figure PCTCN2020137979-appb-000027
在某一优选实施方式中，Z'为
Figure PCTCN2020137979-appb-000028
在某一优选实施方式中，Z'为
Figure PCTCN2020137979-appb-000029
在某一优选实施方式中，Z'为
Figure PCTCN2020137979-appb-000030
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
R 1b-2为
Figure PCTCN2020137979-appb-000031
R 1a-1为R 1a-1-1取代的C 6～C 18的芳基或C 3～C 10的杂芳基；
R 1a-1-1为卤素；
Z为O；
Z'独立地为直键、O、
Figure PCTCN2020137979-appb-000032
R 2为R 2-2取代的C 3～C 10杂芳基；
R 2-2独立地为
Figure PCTCN2020137979-appb-000033
和R 2-1-1为C 1～C 4的烷基。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环；
R 1b-2为
Figure PCTCN2020137979-appb-000034
R 1a-1为R 1a-1-1取代的C 6～C 18的芳基；
R 1a-1-1为卤素；
Z为
Figure PCTCN2020137979-appb-000035
Z'为直键；
R 2为R 2-2取代的C 3～C 10杂芳基；
R 2-2独立地为
Figure PCTCN2020137979-appb-000036
和R 2-1-1为C 1～C 4的烷基。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环；
R 1b-2为
Figure PCTCN2020137979-appb-000037
R 1a-1为R 1a-1-1取代的C 6～C 18的芳基或C 3～C 10的杂芳基；
R 1a-1-1为卤素；
Z'为
Figure PCTCN2020137979-appb-000038
Z为直键或O；
R 2为R 2-2取代的C 3～C 10杂芳基；
R 2-2独立地为
Figure PCTCN2020137979-appb-000039
和R 2-1-1为C 1～C 4的烷基。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环；
R 1b-2为
Figure PCTCN2020137979-appb-000040
R 1a-1为R 1a-1-1取代的C 6～C 18的芳基；
R 1a-1-1为卤素；
Z为直键或O；
Z'为
Figure PCTCN2020137979-appb-000041
R 2为R 2-2取代的C 3～C 10杂芳基；
R 2-2独立地为
Figure PCTCN2020137979-appb-000042
和R 2-1-1为C 1～C 4的烷基。
在某一优选实施方式中，R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环；
R 1b-1为
Figure PCTCN2020137979-appb-000043
R 1a-1为R 1a-1-1取代的C 6～C 18的芳基；
R 1a-1-1独立地为卤素、C 1～C 4的烷基或氰基；
Z'为
Figure PCTCN2020137979-appb-000044
Z为直键；
和R 2为C 3～C 10杂芳基。
在上述任一方案中，当Z'为
Figure PCTCN2020137979-appb-000045
时，其N端可与A相连，C端与R 1-a相连。
在上述任一方案中，当Z'为
Figure PCTCN2020137979-appb-000046
时，其N端可与A相连，S端与R 1-a相连。
在上述任一方案中，当Z'为
Figure PCTCN2020137979-appb-000047
时，其C端可与A相连，Q端与R 1-a相连。
在上述任一方案中，Z和Z'优选不同时为直键。
在上述任一方案中，当Q为C 1～C 4的亚烷基时，所述的C 1～C 4的亚烷基可为亚甲基、亚乙基、亚正丙基、亚异丙基、亚正丁基、
Figure PCTCN2020137979-appb-000048
或亚叔丁基，可以为亚甲基。
在上述任一方案中，当R 1a-1为C 6～C 18的芳基或R 1a-1-1取代的C 6～C 18的芳基时，所述的C 6～C 18的芳基可为C 6～C 14的芳基(例如苯基、萘基、蒽基或菲基)，进一步可以为苯基。
在上述任一方案中，当R 1a-1为R 1a-1-1取代的C 6～C 18的芳基时，所述的R 1a-1-1可位于所述Z'的邻位或间位。
在上述任一方案中，当R 1a-1为R 1a-1-1取代的C 6～C 18的芳基时，所述R 1a-1-1的个数可为1个。
在上述任一方案中，当R 1a-1-1为卤素时，所述的卤素可为F、Cl、Br或I，还可以为F。
在上述任一方案中，当R 1a-1为R 1a-1-1取代的C 6～C 18的芳基时，所述的R 1a-1-1取代的C 6～C 18的芳基可为卤素取代的C 6～C 14的芳基，进一步可为
Figure PCTCN2020137979-appb-000049
更进一步可为
Figure PCTCN2020137979-appb-000050
在上述任一方案中，当R 1a-1为C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基时，所述的C 3～C 10的杂芳基中杂原子为N或S，个数为1个。
在上述任一方案中，当R 1a-1为C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基时，所述的C 3～C 10的杂芳基为C 3～C 5的杂芳基。
在上述任一方案中，当R 1a-1为C 3～C 10的杂芳基时，所述的C 3～C 10的杂芳基可为C 3～C 5的杂芳基、杂原子为N或S、个数为1个，进一步可为吡啶基或噻吩基，更进一步可为
Figure PCTCN2020137979-appb-000051
Figure PCTCN2020137979-appb-000052
更进一步还可为
Figure PCTCN2020137979-appb-000053
在上述任一方案中，当R 1a-1独立地为C 3～C 10的杂环烷基时，所述的C 3～C 10的杂环烷基中的杂原子为N，个数为1。
在上述任一方案中，当R 1a-1独立地为C 3～C 10的杂环烷基时，所述的C 3～C 10的杂环烷基为C 5～C 6的杂环烷基。
在上述任一方案中，当R 1a-1独立地为C 3～C 10的杂环烷基时，所述的C 3～C 10的杂环烷基中为哌啶 基，进一步为
Figure PCTCN2020137979-appb-000054
在上述任一方案中，所述的
Figure PCTCN2020137979-appb-000055
可为
Figure PCTCN2020137979-appb-000056
Figure PCTCN2020137979-appb-000057
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环时，所述的C 3～C 10的杂环中的杂原子可为N，个数为1个。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环，所述的C 3～C 10的杂环中可为C 3～C 5的杂环。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环时，所述的C 3～C 10的杂环可通过杂原子与Z'相连接。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环时，所述的C 3～C 10的杂环可为C 3～C 5的杂环、杂原子为N、杂原子个数为1个，进一步可以为哌啶环(例如
Figure PCTCN2020137979-appb-000058
其中哌啶基上的N原子与Z'相连，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用)。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，所述的R 1b-1取代的C 3～C 10的杂环可为
Figure PCTCN2020137979-appb-000059
Figure PCTCN2020137979-appb-000060
还可以为
Figure PCTCN2020137979-appb-000061
其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环中的杂原子可为N，个数为1个。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环可为C 3～C 9的杂芳环。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环可通过C原子与Z'相连接。
在上述任一方案中，当R 1a和R 1b与其碳相连的原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环可为C 3～C 9的杂芳环、杂原子为N、杂原子个数为1个，进一步可以为吡啶环或喹啉环(例如
Figure PCTCN2020137979-appb-000062
即其中吡啶基通过C原子与Z'相连接，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用)。
在上述任一方案中，当R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环时，所述的R 1b-2取代的C 3～C 10的杂芳环可为
Figure PCTCN2020137979-appb-000063
Figure PCTCN2020137979-appb-000064
还可以为
Figure PCTCN2020137979-appb-000065
Figure PCTCN2020137979-appb-000066
Figure PCTCN2020137979-appb-000067
其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用。
在上述任一方案中，当R 2为C 3～C 10的杂芳基或R 2-2取代的C 3～C 10杂芳基时，所述的C 3～C 10的杂芳基中的杂原子可为N，个数为1个。
在上述任一方案中，当R 2为C 3～C 10的杂芳基或R 2-2取代的C 3～C 10杂芳基时，所述的C 3～C 10的杂芳基可为C 3～C 5的杂芳基。
在上述任一方案中，当R 2为C 3～C 10的杂芳基或R 2-2取代的C 3～C 10杂芳基时，所述的C 3～C 10的杂芳基可为C 3～C 5的杂芳基、杂原子为N、个数为1个，进一步为吡啶基，例如
Figure PCTCN2020137979-appb-000068
在上述任一方案中，当R 2为R 2-2取代的C 3～C 10杂芳基时，所述的R 2-2的个数可为一个。
在上述任一方案中，当R 2-2为
Figure PCTCN2020137979-appb-000069
所述的R 2-1-1为C 1～C 4的烷基时，所述的C 1～C 4的烷基可为甲基、乙基、正丙基、异丙基、正丁基、
Figure PCTCN2020137979-appb-000070
或叔丁基，可以为乙基或
Figure PCTCN2020137979-appb-000071
还可以为
Figure PCTCN2020137979-appb-000072
在上述任一方案中，当R 2为R 2-2取代的C 3～C 10的杂芳基时，所述的R 2-2取代的C 3～C 10的杂芳基可为
Figure PCTCN2020137979-appb-000073
在上述任一方案中，所述的
Figure PCTCN2020137979-appb-000074
可为
Figure PCTCN2020137979-appb-000075
Figure PCTCN2020137979-appb-000076
在某一优选实施方式中，所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药为如下任一化合物：
Figure PCTCN2020137979-appb-000077
Figure PCTCN2020137979-appb-000078
Figure PCTCN2020137979-appb-000079
Figure PCTCN2020137979-appb-000080
本发明还提供一种上述如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药的制备方法，其包括以下步骤：溶剂中，在脱保护试剂存在下，将如式II所示的化合物进行如下式的脱保护反应，得到所述的如式I所示的苯并吡唑类化合物即可；
Figure PCTCN2020137979-appb-000081
其中，R 3为氨基保护基；R 1a、R 1b、R 2和Z的定义均同前所述。
所述的脱保护反应的条件和操作可以为本领域常规的条件和操作，本发明特别优选以下条件和操作。
其中，当R 3为氨保护基时，所述的氨基保护基可以为本领域常规的氨基保护基，优选四氢吡喃(THP)。
其中，所述的溶剂可以为本领域常规的溶剂，优选氯代烃类溶剂，进一步优选二氯甲烷。
其中，所述的脱保护试剂可以为本领域常规的脱保护试剂，优选有机硅烷类化合物(例如三乙级硅烷)和有机酸(例如三氟乙酸)。所述的有机硅烷类化合物与所述的有机酸的摩尔比可以为1:5～1:20，例如1：12。
其中，所述的脱保护反应的温度可以为10～40℃，例如室温。
所述的脱保护反应的进程可以采用本领域常规的方法进行监测(例如TLC、HPLC、核磁)，通常以如式II所示的化合物不再反应或者消失作为反应终点。所述的脱保护反应的时间可以为10～18小时，例如过夜。
所述的反应结束后，还可以进一步包括后处理。所述的后处理包括以下步骤：将反应结束的反应液浓缩、析出固体和柱层析。
所述的后处理步骤中，所述的浓缩的条件和操作均可采用本领域常规的条件和操作。
所述的后处理步骤中，所述的析出固体的条件和操作均可采用本领域常规的条件和操作。所述的 析出固体所用的试剂可为无机碱，进一步优选氨水(例如氨水的浓度为5mol/L)。
所述的后处理步骤中，所述的柱层析的条件和操作均可采用本领域常规的条件和操作。所述的柱层析所用的洗脱剂可为醇类试剂和氯代烃试剂，进一步可以为二氯甲烷和甲醇(例如二氯甲烷和甲醇的体积比为20:1-10:1)。
本发明还提供一种如式II所示的化合物，
Figure PCTCN2020137979-appb-000082
其中，R 3为氨基保护基；R 1a、R 1b、R 2和Z的定义均同前所述。
所述的如式II所示的化合物优选如下任一化合物：
Figure PCTCN2020137979-appb-000083
Figure PCTCN2020137979-appb-000084
本发明还提供了一种所述的如式II所示的化合物的制备方法，其包括以下步骤：溶剂中，在环合试剂存在下，将如式III所示的化合物和如式IV所示的化合物进行如下的环合反应，得到所述的如式II所示的化合物即可；
Figure PCTCN2020137979-appb-000085
其中，R 1a、R 1b、R 2、R 3和Z的定义均同前所述。
所述的环合反应的条件和操作可以为本领域常规的条件和操作，本发明特别优选以下条件和操作。
其中，所述的溶剂可以为本领域常规的溶剂，优选吡咯烷酮类溶剂，进一步优选N-甲基吡咯烷酮。
其中，所述的环合试剂可以为本领域常规的试剂，优选碱金属焦亚硫酸盐(例如焦亚硫酸钠)。
其中，所述的环合试剂与所述的如式III所示的化合物的摩尔比可以为1:1.1～1.2:1，例如1.2:1。
其中，所述的环合反应的温度可以为100～140℃，例如100℃。
所述的环合反应的进程可以采用本领域常规的方法进行监测(例如TLC、HPLC、核磁)，通常以如式II所示的化合物不再反应或者消失作为反应终点。所述的环合护反应的时间可以为10～18小时，例如过夜。
所述的反应结束后，还可以进一步包括后处理。所述的后处理包括以下步骤：将反应结束的反应液冷却至室温、析出固体。
所述的后处理步骤中，所述的析出固体的条件和操作均可采用本领域常规的条件和操作。所述的析出固体所用的试剂为水。
本发明还提供了一种药物组合物，其包括如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，和药用辅料。
本发明还提供了一种如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或上述的药物组合物在制备诱导剂中的应用。
上述的应用中，上所述的诱导剂可以诱导蛋白多糖(Aggrecan)、Ⅱ型胶原(Collagen II)、sox9、Ⅰ型胶原(collagen Ⅰ)、Ⅹ型胶原(collagen Ⅹ)、成骨转录基因(RUNX2)或者碱性磷酸酶(ALP)中的一种或多种基因表达量升高。
上述的应用中，所述的诱导剂可以滑膜干细胞向成软骨和/或成骨细胞进行分化。所述的诱导剂还可以用于骨建造剂、或、治疗或预防牙周病、关节炎(例如类风湿性关节炎、牛皮癣性关节炎、强直性脊柱炎、多关节型幼年特发性关节炎、骨关节炎)、关节损伤、软骨修复、成骨再生、骨质疏松症、骨质减少、脊柱融合、牙周病和骨肿瘤中的一种或多种。
所述的骨建造剂可以增强骨折复原以及在骨移植、关节移植或牙移植的位置刺激骨生长。
本发明还提供了一种如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或上述的药物组合物在制备Wnt途径中一种或多种蛋白的抑制剂中的应用。
上述的应用中，所述的与Wnt途径中一种或多种蛋白相关的疾病可以为癌症、与血管生成异常相疾病、细胞增殖和细胞周期相关的疾病、或、Wnt信号传导组分中的一种或多种的变异或失调造成的疾病。
其中，所述的癌症可以为结肠癌、肝细胞癌、肺癌、卵巢癌、前列腺癌、胰腺癌、骨癌和白血病中的一种或多种。
其中，所述的与血管生成异常相疾病可以为淋巴谱系的造血系统肿瘤、骨髓谱系的造血系统肿瘤、间充质来源的肿瘤、中枢和周围神经系统的肿瘤和黑色素瘤、精原细胞瘤、卡波因氏肉瘤、良性前列腺增生、家族性腺瘤息肉病、神经纤维瘤、动脉粥样硬化、关节炎、肾炎、血管成形术或血管手术后 再狭窄、炎症性肠病、移植排斥、内毒素休克和真菌感染中的一种或多种。
其中，所述的Wnt信号传导组分中的一种或多种的变异或失调造成的疾病可以为结肠息肉病、骨质疏松、假性性神经胶质瘤综合征，家族性渗出性玻璃体视网膜病变、视网膜血管发生、早期冠心病、先天性四肢切断综合征、副中肾管返化和男性化、SERKAL综合征、2型糖尿病、富尔曼综合征、AARRS短肢综合征、牙甲皮肤发育异常，肥胖症，裂手/足畸形，尾侧重复综合征、先天性缺牙、维尔姆斯瘤、骨骼发育异常、灶性皮肤发育不全、神经管缺陷、α地中海贫血综合症、脆性X综合症、ICF综合症、安琪曼综合症、帕一魏二氏综合症、贝一威二氏综合症、诺里病和Rett综合症中的一种或多种。
本发明还提供了一种如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或上述的药物组合物在制备药物中的应用。
上述应用中，所述的药物可以使滑膜干细胞向成软骨和/或成骨细胞进行分化。所述的药物还可以用于骨建造剂、或、治疗或预防牙周病、关节炎(例如类风湿性关节炎、牛皮癣性关节炎、强直性脊柱炎、多关节型幼年特发性关节炎、骨关节炎)、关节损伤、软骨修复、成骨再生、骨质疏松症、骨质减少、脊柱融合、牙周病和骨肿瘤中的一种或多种。
所述的骨建造剂可以增强骨折复原以及在骨移植、关节移植或牙移植的位置刺激骨生长。
上述应用中，所述的药物可以用来治疗和/或预防与Wnt途径中一种或多种蛋白的相关的疾病。
其中，所述的疾病同前所述。
上述应用中，所述的药物中，所述的药物可以用来治疗和/或预防癌症、与血管生成异常相疾病、细胞增殖和细胞周期相关的疾病、或、Wnt信号传导组分中的一种或多种的变异或失调造成的疾病。
其中，所述的癌症、所述的与血管生成异常相疾病、所述的细胞增殖和细胞周期相关的疾病、或、所述的Wnt信号传导组分中的一种或多种的变异或失调造成的疾病均同前所述。
本发明还提供了一种诱导滑膜间充干细胞向成软骨细胞分化、诱导成骨细胞分化或抑制破骨细胞形成的方法，其包括给予受试者(优选给受试者治疗有效量的)需要治疗对象上述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或上述的药物组合物。
所述的受试者可以哺乳动物，进一步可以为人。
所述的成软骨细胞和/或成骨细胞来源于滑膜间充质干细胞的分化。MSC是多能干细胞，其可以分化成几种不同类型的细胞，包括但不限于成骨细胞，软骨细胞和脂肪细胞。分化是由较不特化的细胞类型形成的特化细胞类型的过程，例如来自MSC的软骨细胞。
所述的软骨细胞由蛋白多糖(Aggrecan)、Ⅱ型胶原(Collagen II)和sox9中的一种或者多种基因的表达产生或维持。
所述的促进成骨分化作用和抑制破骨细胞形成由Ⅰ型胶原(collagen Ⅰ)、Ⅹ型胶原(collagen Ⅹ)、成骨转录基因(RUNX2)或碱性磷酸酶(ALP)中的一种或者多种基因的表达产生或维持。
本发明还提供了一种治疗或预防与Wnt途径中一种或多种蛋白相关疾病的方法，其包括给予受试者(优选给受试者治疗有效量的)需要治疗对象上述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或上述的药物组合物。
所述的疾病均同前所述。
术语“多个”是指2个、3个、4个或5个。
术语“药学上可接受的”是指盐、溶剂、辅料等一般无毒、安全，并且适合于患者使用。所述的“患者”优选哺乳动物，更优选为人类。
术语“药学上可接受的盐”是指本发明化合物与相对无毒的、药学上可接受的酸或碱制备得到的盐。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的药学上可接受的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括但不限于：锂盐、钠盐、钾盐、钙盐、铝盐、镁盐、锌盐、铋盐、铵盐、二乙醇胺盐。当本发明的化合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的药学上可接受的酸与这类化合物的中性形式接触的方式获得酸加成盐。所述的药学上可接受的酸包括无机酸，所述无机酸包括但不限于：盐酸、氢溴酸、氢碘酸、硝酸、碳酸、磷酸、亚磷酸、硫酸等。所述的药学上可接受的酸包括有机酸，所述有机酸包括但不限于：乙酸、丙酸、草酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、水杨酸、酒石酸、甲磺酸、异烟酸、酸式柠檬酸、油酸、单宁酸、泛酸、酒石酸氢、抗坏血酸、龙胆酸、富马酸、葡糖酸、糖酸、甲酸、乙磺酸、双羟萘酸(即4,4’-亚甲基-双(3-羟基-2-萘甲酸))、氨基酸(例如谷氨酸、精氨酸)等。当本发明的化合物中含有相对酸性和相对碱性的官能团时，可以被转换成碱加成盐或酸加成盐。具体可参见Berge et al.,"Pharmaceutical Salts",Journal of Pharmaceutical Science 66:1-19(1977)、或、Handbook of Pharmaceutical Salts:Properties,Selection,and Use(P.Heinrich Stahl and Camille G.Wermuth,ed.,Wiley-VCH,2002)。
术语“化合物”和“药学上可接受的盐”可以以晶型或无定型的形式存在。术语“晶型”是指其中的离子或分子是按照一种确定的方式在三维空间作严格周期性排列，并具有间隔一定距离周期重复出现规律；因上述周期性排列的不同，可存在多种晶型，也即多晶型现象。
术语“化合物”和“药学上可接受的盐”如存在立体异构体，则可以以单一的立体异构体或它们的混合物(例如外消旋体)的形式存在。
术语“立体异构体”是指顺反异构体或旋光异构体。这些立体异构体可以通过不对称合成方法或手性分离法(包括但不限于薄层色谱、旋转色谱、柱色谱、气相色谱、高压液相色谱等)分离、纯化及富集，还可以通过与其它手性化合物成键(化学结合等)或成盐(物理结合等)等方式进行手性拆分获得。
术语“单一的立体异构体”是指本发明化合物的一种立体异构体相对于该化合物的所有立体异构体的质量含量不低于95％。
术语“化合物”和“药学上可接受的盐”如存在互变异构体，则可以以单一的互变异构体或它们的混合物的形式存在，较佳地以较稳定的互变异构体为主的形式存在。
术语“化合物”和“药学上可接受的盐”中的原子可以以其天然丰度或非天然丰度的形式存在。以氢原子为例，其天然丰度的形式是指其中约99.985％为氕、约0.015％为氘；其非天然丰度的形式是指其中约95％为氘。也即，术语“化合物”和“药学上可接受的盐”中的一个或多个原子可为以非天然丰度的形式存在的原子。
术语“卤素”是指氟、氯、溴或碘。
术语“烷基”是指具有指定的碳原子数的直链或支链烷基。烷基的实例包括甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、正戊基、正己基、正庚基、正辛基及其类似烷基。
术语“烷氧基”是指基团-O-R X，其中，R X为如上文所定义的烷基。
术语“环烷基”是指单价饱和的环状烷基，优选具有3-7个环碳原子、更优选3-6个碳原子的单价饱和的环状烷基，例如环丙基、环丁基、环戊基或环己基。
术语“杂环烷基”是指具有杂原子的饱和的单环基团，优选含有1个、2个或3个独立地选自N、O和S的环杂原子的3-7元饱和的单环。杂环烷基的示例为：吡咯烷基、四氢呋喃基、四氢吡喃基、四氢噻吩基、四氢吡啶基、四氢吡咯基、氮杂环丁烷基、噻唑烷基、唑烷基、哌啶基、吗啉基、硫代吗啉基、哌嗪基、氮杂环庚烷基、二氮杂环庚烷基、氧氮杂环庚烷基等。优选的杂环基为吗啉-4-基、哌啶-1-基、吡咯烷-1-基、硫代吗啉-4-基和1,1-二氧代-硫代吗啉-4-基。
术语“芳基”是指具有4n+2芳香族环系统(例如，在循环阵列中具有6，10，或14个共享的p电子)的基团。上述芳基单元的实例包括苯基、萘基、菲基、或者蒽基。
术语“杂芳基”是指含有杂原子的芳香基团，优选含有1个、2个或3个独立地选自氮、氧和硫的芳族5-6元单环或9-10元双环，例如呋喃基、吡啶基、哒嗪基、嘧啶基、吡嗪基、噻吩基、异唑基、噁唑基、二唑基、咪唑基、吡咯基、吡唑基、三唑基、四唑基、噻唑基、异噻唑基、噻二唑基、苯并咪唑基、吲哚基、吲唑基、苯并噻唑基、苯并异噻唑基、苯并唑基、苯并异唑基、喹啉基、异喹啉基等。
术语“药用辅料”是指生产药品和调配处方时使用的赋形剂和附加剂，是除活性成分以外，包含在药物制剂中的所有物质。可参见中华人民共和国药典(2015年版)四部、或、Handbook of Pharmaceutical Excipients(Raymond C Rowe,2009 Sixth Edition)。
术语“治疗有效量”是指产生治疗效果的剂量。确切的剂量将取决于治疗的目的，并且本领域技术人员可以使用已知技术确定(参见，例如，Lieberman，Pharmaceutical Dosage Forms(vols.1-3,1992)；Lloyd，The Pharmaceutical，Science and Technology of Pharmaceutical Compounding(1999)；Pickar，Dosage Calculations(1999)；和Remington：The Science and Practice of Pharmacy，20th Edition，2003，Gennaro，Ed.，Lippincott，Williams&Wilkins)。
在不违背本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于：本发明的苯并吡唑类化合物对蛋白多糖、Ⅱ型胶原、sox9、Ⅰ型胶原、Ⅹ型胶原、成骨转录基因和碱性磷酸酶中的一种或多种具有较好的诱导作用，进而可以用来治疗和/或改善相关的疾病和病症。
具体实施方式
中间体的制备
中间体化合物IV-20000-6的制备
Figure PCTCN2020137979-appb-000086
第一步:3-溴-5-硝基吡啶-4-胺
室温下，向3-硝基吡啶-4-胺(100g,0.716mol)和乙酸钠(177.2g,2.21mol)的乙酸溶液(800mL)中滴加入溴(44.4mL,0.864mol)。反应液在110℃搅拌过夜。TLC显示反应完毕，浓缩反应液，用碳酸钠水溶液调解PH到9-10，搅拌15分钟，过滤，滤饼用正己烷/乙酸乙酯(200mL x2,10/1)洗涤,干燥后得到3-溴-5-硝基吡啶-4-胺(116g,收率74％)，黄色固体。
MS(ESI):219.7[M+1]
1H NMR(400MHz,DMSO-d 6)ppm 8.97(s,1H),8.54(s,1H),7.82(s,2H).
第二步:3-(3-氟苯基)-5-硝基吡啶-4-胺
向三口反应瓶中依次加入3-溴-5-硝基吡啶-4-胺(50.0g,230.41mmol),(3-氟苯基)硼酸(38.71g,276.50mmol)，碳酸钠(61.1g,576.0mmol)，双三苯基膦合二氯化钯(8.06g,11.52mmol)，1,4-二氧六环/水(600mL,3/1)，氮气保护，95℃下搅拌过夜。TLC显示反应完毕，过滤，浓缩滤液，粗品用硅胶柱纯化(洗脱剂：10％-50％乙酸乙酯/正己烷)，得到(3-氟苯基)-5-硝基吡啶(30.5g,收率59％)，黄色固体。
MS(ESI):234.2[M+1]
1H NMR(400MHz,DMSO-d 6)ppm 9.04(s,1H),8.12(s,1H),7.61-7.55(m,1H),7.41(s,2H),7.34-7.26(m,2H).
第三步:5-(3-氟苯基)吡啶-3,4-二胺
向500毫升三口瓶中依次加入3-(3-氟苯基)-5-硝基吡啶-4-胺(30.5g,130.90mmol)，Pd/C(5.0g)，甲醇(500mL)，通入氢气，室温搅拌过夜。TLC显示反应完毕，过滤，浓缩滤液，粗品用乙醚洗涤(50mL x 2)，得到黄色固体5-(3-氟苯基)吡啶-3,4-二胺(20.1g,收率75％)。
MS(ESI):203.9[M+1].
1H NMR(400MHz,DMSO-d 6)ppm 7.68(s,1H),7.53-7.47(m,1H),7.45(s,1H),7.24-7.17(m,3H),5.08(s,2H),4.72(s,2H).
13C NMR(400MHz,DMSO-d 6)ppm 164.1 161.6,140.0,139.9,139.8,138.3,134.9,131.4,131.3,131.2,125.6,120.3,116.3,116.1,114.5,114.3.
中间体化合物IV-23000-2的制备
Figure PCTCN2020137979-appb-000087
第一步:N-(4-氨基-5-硝基吡啶-3-基)烟酰胺
向100毫升单口瓶依次加入烟酸(2.6g,21mmol)、二氯甲烷(20mL)、DMF(77mg,1.1mmol)，氮气保护下，0℃滴加草酰氯(5.3g,42mmol)，室温搅拌2h。浓缩得到烟碱酰氯盐酸盐粗品。
向100毫升单口瓶中依次加入5-硝基吡啶-3,4-二胺(2g,13mmol)，吡啶(40mL)，氮气保护下，0℃分批加入上述烟碱酰氯盐酸盐粗品(3g,19mmol)，0℃搅拌2h。TLC显示反应完毕。加入正己烷(20mL)，过滤，滤饼用二氯甲烷洗涤，干燥得到粗品。柱纯化，(洗脱剂：5％甲醇/二氯甲烷)，得到黄色固体N-(4-氨基-5-硝基吡啶-3-基)烟酰胺(1.3g,收率38％)。MS(ESI)：C 11H 9N 5O 3:260.0[M+1].
第二步:N-(4,5-二氨基吡啶-3-基)烟酰胺
向100毫升单口瓶中依次加入N-(4-氨基-5-硝基吡啶-3-基)烟酰胺(2g,7.7mmol)，甲醇(40mL)，Pd/C(250mg)，通入氢气，反应液在室温下搅拌16h。TLC显示反应完毕。过滤，浓缩滤液。洗涤：二氯甲烷/甲醇(3mL,10:1),得到淡黄色固体N-(4,5-二氨基吡啶-3-基)烟酰胺(1.1g,收率59％)。
MS(ESI)：C 11H 11N 5O:230.0[M+1].
1HNMR(400MHz,DMSO-d 6)ppm：9.86(s,1H),9.17(s,1H),8.75(d,J＝3.2Hz,1H),8.34(d,J＝7.2Hz,1H),7.61-7.54(m,3H),5.50(s,2H),4.82(s,2H).
13CNMR(400MHz,DMSO-d 6)ppm：165.43,152.68,149.74,144.32,136.35,133.19,131.00,129.94,123.78,120.87,117.61.
中间体化合物III-22000-A的制备
Figure PCTCN2020137979-appb-000088
1、中间体化合物2的合成
冰浴下，向化合物1(5g，37.3mmol)和咪唑(4.7g，74.6mmol)的50mL DMF溶液中缓慢加入叔丁基二甲基氯硅烷(7.28g，48.5mmol)。反应液升至室温，在室温下继续搅拌3小时。反应液中加入300mL水稀释，溶液用乙酸乙酯萃取两次，有机相旋干，剩余物用硅胶柱(EA：PE＝1:5)纯化得8.3g淡黄色固体，收率90％。
MS(ESI)m/z＝290.2[M+H+CH 3CN] +.
2、中间体化合物3的合成
室温下，向含有化合物2(8.3g,33.5mmol)的100mL DCM溶液中加入NIS(9g，40.2mmol)。反应常温搅拌3小时。有机相分别用水和硫代硫酸钠溶液洗涤。有机层经无水硫酸钠干燥后旋干，剩余物用硅胶柱纯化(EA：PE＝1:3)得10.5g黄色固体，收率84％。
MS(ESI)m/z＝375.0[M+H] +.
3、中间体化合物4的合成
室温下，向含有化合物3(10.5g,28.1mmol)和DHP(4.7g，56.1mmol)的100mL DCM和30mL四氢呋喃混合溶液溶液中加PTSA(0.53g，2.81mmol)。反应液在室温搅拌3小时。溶液旋干，剩余物用硅胶柱(EA：PE＝1:4)纯化得9.5g淡褐色油状物，收率74％。
MS(ESI)m/z＝459.1[M+H] +.
4、中间体化合物5的合成
在高压反应釜内，向含有化合物4(9.5g,20.7mmol)和TEA(6.28g，62.2mmol)的100mL甲醇溶液中加PdCl2(dppf)(1.62g,2.07mmol)。反应釜内加入10个大气压的CO气体。该反应在60℃下搅拌5小时。冷却至室温，用硅藻土过滤，滤液旋干，剩余物用硅胶柱(EA：PE＝1:10)纯化得7.8g无色油状物，收率96％。
MS(ESI)m/z＝391.2[M+H] +.
5、中间体化合物6的合成
干冰丙酮浴下，向含有化合物5(7.8g,20mmol)100mL无水四氢呋喃溶液中加入四氢铝锂(1.52g，40mmol)。该溶液在-40℃下反应1小时。反应用NH4Cl溶液淬灭，溶液用乙酸乙酯萃取两次。有 机层旋干，剩余物用硅胶柱(EA：PE＝1:5)纯化得6.8g白色固体，收率90％。
MS(ESI)m/z＝363.3[M+H] +.
6、中间体化合物7的合成
冰浴下，向含有化合物6(6.8g,18.7mmol)和TEA(5.69g，56.4mmol)的100mL二氯甲烷溶液中滴加入乙酰氯(1.9g，24.4mmol)。该溶液在室温下反应2小时。用NaHCO3水溶液淬灭，溶液用乙酸乙酯萃取，有机相旋干，粗产品用硅胶柱(EA：PE＝1:4)纯化的6.8g白色固体，收率89％。
MS(ESI)m/z＝405.1[M+H] +.
7、中间体化合物8的合成
室温下，向含有化合物7(6.8g,16.8mmol)的80mL四氢呋喃溶液中加入TBAF(8.8g，33.6mmol)。该溶液在室温下搅拌16小时。溶剂旋干，剩余物用乙酸乙酯稀释，然后用水洗涤三次。有机相经无水硫酸钠干燥，过滤，滤液旋干得粗产品5.3g白色固体，该粗产品直接用于下一步反应。
MS(ESI)m/z＝291.0[M+H] +.
8、中间体化合物9的合成
含有化合物8(5.3g,18.3mmol)，3-氟-5硝基吡啶(2.6g，18.3mmol)和K 2CO 3(7.6g，54.8mmol)的100mL DMF溶液加热到100℃，并在此温度下反应3小时。反应液倒入500mL水中，溶液用乙酸乙酯萃取，有机相旋干，粗产品用硅胶柱(EA：PE＝1:3)得6.2g黄色固体，收率82％。
MS(ESI)m/z＝413.1[M+H] +.
9、中间体化合物10的合成
Figure PCTCN2020137979-appb-000089
室温下，向含有化合物9(6.2g,15mmol)的80mL甲醇溶液中加入Pd/C(1g)。该溶液在氢气条件下常温搅拌2小时。硅藻土过滤，滤液旋干得5g粗产品，该粗产品直接用于下一步反应。
MS(ESI)m/z＝383.2[M+H] +.
10、中间体化合物11的合成
冰浴下，向含有化合物10(1g,6.57mmol)和TEA(2g，19.mmol)的10mL无水二氯甲烷溶液中滴加异戊酰氯(0.87g7.23mmol)。该溶液在室温下反应2小时。溶液旋干，剩余物用硅胶柱(EA：PE＝1:3)纯化得1.2g白色固体(MS，收率77％。ESI)m/z＝467.3[M+H] +.
11、中间体化合物12的合成
室温下，向含有化合物11(2.6g,4.78mmol)的20mL四氢呋喃溶液中滴加LiOH(0.4g，9.58mmol)的3mL水溶液。该溶液在室温下反应2小时。用稀盐酸调PH至弱酸性。溶液用乙酸乙酯萃取，有机相旋干，粗产品用反相制备柱纯化的1.5g灰色固体，该粗产品直接用于下一步反应。
MS(ESI)m/z＝425.1[M+H] +.
12、III-22000-A的合成
室温下，向含有化合物12(1.6g,4.05mmol)的20mL乙酸乙酯溶液中加入MnO2(0.7g,8.1mmol)。该溶液在室温下反应2小时。硅藻土过滤，滤液旋干，粗产品用反相制备柱纯化的1.1g淡黄色固体，收率69％。
MS(ESI)m/z＝423.1[M+H] +.
1H NMR(400MHz,DMSO)ppm：δ10.24(s,1H),10.16(s,1H),8.58(d,J＝1.7Hz,1H),8.14(d,J＝2.4Hz,1H),8.03(d,J＝9.1Hz,1H),7.74(t,J＝2.1Hz,1H),7.69(d,J＝2.2Hz,1H),7.44(dd,J＝9.1,2.3Hz,1H),6.10(dd,J＝9.3,2.2Hz,1H),3.97–3.75(m,2H),2.47–2.33(m,1H),2.18(d,J＝7.1Hz,2H),2.13–1.95(m,3H),1.81(d,J＝6.5Hz,1H),1.64(d,J＝3.4Hz,2H),0.90(s,3H),0.89(s,3H).
中间体化合物III-22000-B的制备
Figure PCTCN2020137979-appb-000090
1、中间体13的合成
冰浴下，向含有化合物10(1g,6.57mmol)和TEA(2g，19.7mmol)的10mL无水二氯甲烷溶液中滴加丙酰氯(0.87g，7.23mmol)。该溶液在室温下反应2小时。溶液旋干，剩余物用硅胶柱(EA：PE＝1:3)纯化得1.2g白色固体，收率77％
MS(ESI)m/z＝439.3[M+H] +.
2、中间体14的合成
室温下，向含有化合物13(2.6g,4.78mmol)的20mL四氢呋喃溶液中滴加LiOH(0.4g，9.58mmol)的3mL水溶液。该溶液在室温下反应2小时。用稀盐酸调PH至弱酸性。溶液用乙酸乙酯萃取，有机相旋干，粗产品用反相制备柱纯化的1.5g灰色固体，该粗产品直接用于下一步反应。
MS(ESI)m/z＝397.1[M+H] +.
3、III-22000-B的合成
室温下，向含有化合物14(1.6g,4.05mmol)的20mL乙酸乙酯溶液中加入MnO 2(0.7g,8.1mmol)。该溶液在室温下反应2小时。硅藻土过滤，滤液旋干，粗产品用反相制备柱纯化得1.1g白色固体，收率89％。
MS(ESI)m/z＝395.2[M+H] +.
1H NMR(400MHz,DMSO)ppm:δ10.19(s,1H),10.16(s,1H),8.55(s,1H),8.14(d,J＝2.4Hz,1H),8.03(d,J＝9.1Hz,1H),7.73(s,1H),7.68(d,J＝2.0Hz,1H),7.43(dd,J＝9.1,2.3Hz,1H),6.14–6.06(m,1H),3.97–3.76(m,3H),2.45-2.36(m,1H),2.31(q,J＝7.5Hz,2H),2.12-2.06(m,2H),1.85-1.75(m,1H),1.66-1.61(m,2H),1.03(t,J＝7.5Hz,3H).
中间体化合物III-22000-C的制备
Figure PCTCN2020137979-appb-000091
1、中间体2的合成
常温下，向含有化合物1(30g,133.3mmol)和DHP(33.64g,399.9mmol)的二氯甲烷(300mL)溶液中加入PTSA(2.53g,13.3mmol)。反应液在常温条件下搅拌16个小时，浓缩，剩余物用硅胶柱纯化(PE:EA＝10:1)得白色固体27g(MS(ESI)m/z＝309.1[M+H] +)。
2、中间体4的合成
向含有化合物2(15.6g,50.5mmol)，化合物3(10.1g，45.9mmol)和Na 2CO 3(14.46g，137.7mmol)的乙腈(300mL)和水(60mL)的混合溶液中加入PdCl 2(dppf)(1.68g，2.3mmol)。该溶液用氮气保护升温至100℃，反应3小时。冷却至室温，用硅藻土过滤，滤液旋干，剩余物直接用于下一步，没有更远的纯化。得灰褐色固体18.6g。
MS(ESI)m/z＝323[M+H] +.
3、III-22000-C的合成
冰浴下，向含有化合物4(18.6g,57.76mmol)和TEA(17.05g,173.3mmol)的DCM(500mL)溶液中滴加入化合物5(9.01g,75.09mmol)。反应液升至室温并在室温下搅3小时。反应液倒入500mL水中。溶液用DCM萃取两次，合并有机相，干燥，移除溶剂，用反相快速制备色谱仪纯化得到黄色固体10.3g，收率48％。
MS(ESI)m/z＝407.2[M+H] +.
1H NMR(400MHz,DMSO)ppm:δ10.23(s,2H),8.81(d,J＝2.2Hz,1H),8.64(d,J＝2.0Hz,1H),8.39(m,J＝8.4,6.3Hz,2H),8.06(d,J＝8.8Hz,1H),7.91(m,J＝8.8,1.6Hz,1H),6.13(m,J＝9.3,2.3Hz,1H),4.03–3.75(m,2H),2.47–2.38(m,1H),2.27(d,J＝7.1Hz,2H),2.20–1.97(m,3H),1.89–1.71(m,1H),1.71–1.59(m,2H),0.97(d,J＝6.6Hz,6H).
中间体化合物III-24000-A的制备
Figure PCTCN2020137979-appb-000092
1、中间体2的合成
冰浴下，向NaNO 2(17g，0.25mmol)的50mL水和90mL的DMF的混合溶液中滴加入30mLHCl(2N)溶液，然后再加入化合物1(5g，31.05mmol)的90mLDMF溶液。反应液升温至50℃然后保持此温度继续搅拌3小时。冷却至室温。过滤，滤饼用冷水洗涤，干燥的粗产品4.27g。该粗产品直接用于下一步反应。
MS(ESI)m/z＝191[M+H] +.
2、中间体3的合成
冰浴下，向含有化合物2(4.27g,22.5mmol)的50mL无水甲醇溶液中滴加SOCl 2(3.47g，29.2mmol)。该溶液升温至65℃，反应4小时。溶液旋干，剩余物用硅胶柱纯化(EA：PE＝1:1)得4.5g白色固体，收率98％。
MS(ESI)m/z＝205[M+H] +.
3、中间体5的合成
室温下，向含有化合物3(4.5g,22.1mmol)和DHP(3.71g，44.1mmol)的50mL的DCM溶液中加入PTSA(0.4g，2.21mmol)。反应过夜。溶液旋干，剩余物用硅胶柱纯化(EA：PE＝1:1)得3.2g白色固体，收率50％。
MS(ESI)m/z＝289[M+H] +.
4、中间体6的合成
冰浴下，向含有化合物5(2.6g,9.02mmol)的30mL无水四氢呋喃溶液中滴加NaBH 4(0.68g，18.lmmol)。保持0℃反应1小时。用水淬灭，溶液用乙酸乙酯萃取两次。有机相合并旋干2.5g白色固体，该粗产品直接用于下一步反应。
MS(ESI)m/z＝291[M+H] +.
5、中间体7的合成
室温下，向含有化合物6(2.5g,8.62mmol)的20mL四氢呋喃溶液中滴加LiOH(0.72g，17.2mmol)的3mL水溶液。该溶液在室温下反应2小时。溶液旋干，剩余物用反相制备柱纯化得2.4g白色固体，收率98％。
MS(ESI)m/z＝277[M+H] +.
6、中间体9的合成
冰浴下，向含有化合物7(2.4g,8.7mmol)和化合物8(1.04g，9.56mmol)的20mLDMF溶液中加入HATU(4.3g，11.3mmol)和DIPEA(3.36g，26.1mmol)。该溶液升至室温，反应2小时。反应液倒入100mL水中，溶液用乙酸乙酯萃取两次。有机相旋干，剩余物用硅胶柱纯化(EA：PE＝1:1)得2.6g白色固体，收率81％。
MS(ESI)m/z＝368[M+H] +.
7、中间体11的合成
冰浴下，向含有化合物9(2.6g,7.08mmol)和TEA(2.14g，21.2mmol)的20mLDMF溶液中滴加化合物10(2.13g，17.7mmol)。该溶液升至室温，反应2小时。反应液倒入100mL水中，溶液用乙酸乙酯萃取两次。有机相旋干得粗产品2.7g白色固体，该粗产品直接用于下一步反应。
MS(ESI)m/z＝536[M+H] +.
8、中间体12的合成
室温下，向含有化合物11(2.7g,5.05mmol)的20mL四氢呋喃溶液中滴加LiOH(0.25g，6.05mmol)的3mL水溶液。该溶液在室温下反应2小时。用稀盐酸调PH至弱酸性。溶液用乙酸乙酯萃取，有机相旋干得粗产品2.1g白色固体。该粗产品直接用于下一步反应。
MS(ESI)m/z＝452[M+H] +.
9、III-24000-A的合成
常温下，向含有化合物12(2.1g,4.66mmol)的20mL乙酸乙酯溶液中加入MnO 2(0.81g,9.31mmol)。反应液在室温下搅拌16小时。过滤，滤液旋干，剩余物用反相快速制备色谱仪纯化得到1.1g白色固体，三步总收率35％。
MS(ESI)m/z＝450[M+H] +.
1H NMR(400MHz,DMSO)δ10.84(s,1H),10.33(s,1H),10.25(s,1H),8.86(s,1H),8.77(d,J＝2.0Hz,1H),8.71(s,1H),8.60(d,J＝1.9Hz,1H),8.17(dd,J＝8.9,1.4Hz,1H),8.06(d,J＝8.9Hz,1H),6.15(dd,J＝9.3,2.3Hz,1H),3.95-3.90(m，1H),3.88–3.78(m,1H),2.48-2.39(m,1H),2.26(d,J＝7.1Hz,2H),2.20–2.00(m,3H),1.87-1.74(m,1H),1.68-1.60(m,2H),0.97(s,3H),0.95(s,3H).
中间体化合物III-24000-B的制备
Figure PCTCN2020137979-appb-000093
1、中间体2的合成
冰浴下，向NaNO 2(33g，0.47mol)的95mL水和180mL的DMF的混合溶液中滴加入200mL HCl(2N)溶液，然后再加入化合物1(10g，0.062mol)的180mL DMF溶液。反应液升温至80℃然后保持此温度继续搅拌3小时。冷却至室温。加入1L水稀释，溶液用乙酸乙酯萃取，有机相旋干，剩余物用硅胶柱(EA：PE＝1:3)纯化得3g淡黄色固体(MS(ESI)m/z＝190.1[M-H] +)，收率26％。
2、中间体3的合成
室温下，向含有化合物2(3g,15.7mmol)和DHP(2.64g，31.4mmol)的20mL DCM和20mL四氢呋喃混合溶液中加入PTSA(0.3g，1.57mmol)。反应常温搅拌过夜。溶液旋干，剩余物用硅胶柱纯化(DCM：PE＝1:3)得3.8g白色固体(MS(ESI)m/z＝317.2[M+H+CH 3CN] +)，收率88％。
3、中间体4的合成
冰浴下，向含有化合物3(3.8g,13.8mmol)的30mL无水四氢呋喃溶液中滴加NaBH 4(1.05g，27.6mmol)。保持0℃反应1小时。用水淬灭，溶液用乙酸乙酯萃取两次。有机相合并旋干3.3g白色固体(MS(ESI)m/z＝277.2[M+H] +)，该粗产品直接用于下一步反应。
4、中间体5的合成
室温下，向含有化合物4(3.3g,11.9mmol)的30mL甲醇溶液中加Pd/C(0.33g)。该溶液在氢气球条件下搅拌3小时。用硅藻土过滤，滤液旋干2.3g油状物(MS(ESI)m/z＝247.0[M+H] +)，该粗产品直接用于下一步反应。
5、中间体7的合成
冰浴下，向含有化合物6(1g,6.57mmol)和TEA(2g，19.7mmol)的10mL无水二氯甲烷溶液中滴加异戊酰氯(0.87g，7.23mmol)。该溶液在室温下反应2小时。溶液旋干，剩余物用硅胶柱(EA：PE＝1:3)纯化得1.2g白色固体(MS(ESI)m/z＝237.0[M+H] +)，收率77％。
6、中间体8的合成
室温下，向含有化合物7(1.2g,5.08mmol)的10mL四氢呋喃溶液中滴加LiOH(0.26g，6.1mmol)的2mL水溶液。该溶液在室温下反应2小时。用稀盐酸调PH至弱酸性。溶液用乙酸乙酯萃取，有机相 旋干，粗产品用反相制备柱纯化的1g灰色固体(MS(ESI)m/z＝223.1[M+H] +)，收率89％。
7、中间体9的合成
冰浴下，向含有化合物8(1g,4.5mmol)和化合物5(1.11g，4.5mmol)的20mL DMF溶液中加入HATU(2.23g，5.85mmol)和DIPEA(1.74g,13.5mmol)。该溶液在室温下搅拌1小时。反应液倒入100mL水中，溶液用乙酸乙酯萃取两次。有机相旋干得粗产品1.6g白色固体(MS(ESI)m/z＝452.1[M+H] +)，该粗产品直接用于下一步反应。
8、III-24000-B的合成
常温下，向含有化合物9(1.6g,3.55mmol)的20mL乙酸乙酯溶液中加入MnO 2(0.62g,7.09mmol)。该混合物在室温下搅拌16小时。硅藻土过滤，滤液旋干，剩余物用反相快速制备色谱仪纯化得到1.02g白色固体(MS(ESI)m/z＝450.3[M+H] +)，两步总收率50％。
1H NMR(400MHz,DMSO)ppm:δ10.69(s,1H),10.33(s,1H),10.18(s,1H),8.94(d,J＝2.3Hz,1H),8.86(d,J＝1.6Hz,1H),8.70(s,1H),8.57(s,1H),7.92(s,2H),6.05(d,J＝7.6Hz,1H),3.96-3.90(m,1H),3.86–3.74(m,1H),2.44-2.38(m,1H),2.27(d,J＝7.1Hz,2H),2.19–1.96(m,3H),1.85-1.75(m,1H),1.66-1.61(m,2H),0.97(s,3H),0.96(s,3H).
中间体化合物IV-22000-1的制备
Figure PCTCN2020137979-appb-000094
第一步:3-溴-5-硝基吡啶-4-胺
向500毫升三口瓶中依次加入3-硝基吡啶-4-胺(25g,0.179mol)、乙酸钠(44.3g,0.540mol)、冰醋酸(200mL)，室温下滴加溴(11.1mL,0.216mol)，反应液在110℃搅拌过夜。TLC显示反应完毕，浓缩，用碳酸钠调pH＝9-10，搅拌15分钟，过滤，滤饼用正己烷/乙酸乙酯(50mL x2,10/1)洗涤，干燥得3-溴-5-硝基吡啶-4-胺(35g,收率74％)，黄色固体。
MS(ESI):C 5H 4BrN 3O 2，219.6[M+1].
1HNMR(400MHz,DMSO-d 6)ppm:8.97(s,1H),8.54(s,1H),7.92-7.72(m,2H).
第二步:3-(2-氟苯基)-5-硝基吡啶-4-胺
向500毫升三口瓶中依次加入3-溴-5-硝基吡啶-4-胺(15g,68.8mmol)，(2-氟苯基)硼酸(11.55g,82.56mmol)和碳酸钠(21.88g,206.4mmol)，然后加入双(三苯基膦)合氯钯(2.41g,34.33mmol)、1,4-二氧六环/水(700mL,3/1)。氮气保护下，95℃搅拌过夜。TLC显示反应完毕，过滤，浓缩滤液得粗品，柱纯化(洗脱剂：10％-50％乙酸乙酯：正己烷)。得到棕色固体3-(2-氟苯基)-5-硝基吡啶-4-胺(14.9g,收率93％)。
MS(ESI)C 11H 8FN 3O 2:234.0[M+1].
1HNMR(400MHz,DMSO-d 6)ppm:9.07(s,1H),8.12(s,1H),7.57-7.55(m,1H),7.45-7.40(m,2H),7.38-7.35(m,2H).
第三步:5-(2-氟苯基)吡啶-3,4-二胺
将3-(2-氟苯基)-5-硝基吡啶-4-胺(3.9g,16.73mmol)和Pd/C(570mg)置于甲醇(80mL)通入氢气，室温搅拌过夜。TLC显示反应完毕，过滤，浓缩滤液。粗品柱纯化，洗脱剂：正己烷/二氯甲烷(1L,4/1)，得到白色固体5-(2-氟苯基)吡啶-3,4-二胺(3.0g,收率88％)。
MS(ESI)：C 11H 10FN 3，204.1[M+1]
1HNMR(400MHz,DMSO-d 6)ppm:7.69(s,1H),7.45-7.47(m,1H),7.39(s,1H),7.27-7.35(m,3H),4.95(s,2H),4.70(s,2H).
13CNMR(400MHz,DMSO-d 6)ppm 159.0&162.4,140.51,139.13,135.09,132.52,131.16,130.17,125.27,124.50,116.47,115.6.
中间体化合物IV-22000-2的制备
Figure PCTCN2020137979-appb-000095
第一步:3-硝基-5-(噻吩-2-基)吡啶-4-胺
向100毫升单口瓶中依次加入3-溴-5-硝基吡啶-4-胺(6g,27.6mmol),噻吩-2-基硼酸(4.2g,33.2mmol),双(三苯基膦)二氯合钯(967mg,1.38mmol),碳酸钠(7.3g,69mmol)，然后加入二氧六环(60mL)和水(20mL)，氮气保护下，90℃搅拌16h。TLC显示反应完毕。过滤，浓缩滤液，粗品用乙酸乙酯(200mL)萃取，水洗(100mL).食盐水(50mL)洗涤，干燥，浓缩，柱色谱纯化(洗脱剂：10％乙酸乙酯/正己烷)，得到黄色固体3-硝基-5-(噻吩-2基)吡啶-4-胺(4.8g,76％)。
MS(ESI)C 9H 7N 3O 2S:222.1[M+1]
1HNMR(400MHz,DMSO-d 6)ppm:9.03(s,1H),8.25(s,1H),7.78(d,J＝5.07Hz,1H),7.51(s,2H),7.34(d,J＝2.8Hz,1H),7.26(dd,J＝5.0,3.6Hz,1H),
第二步:5-(噻吩-2-基)吡啶-3,4-二胺
向100毫升单口瓶加入3-硝基-5-(噻吩-2-基)吡啶-4-胺(1.8g,8.1mmol)，甲醇(30mL)，Pd/C(150mg)，通入氢气，室温搅拌16h。TLC显示反应完毕。过滤，浓缩得到粗品，用二氯甲烷/正己烷(10mL,1:5)洗涤，抽滤得到白色固体5-(噻吩-2-基)吡啶-3,4-二胺(1.2g,收率77％)。
MS(ESI)C 9H 9N 3S:192.0[M+1].
1HNMR(400MHz,DMSO-d 6)ppm 7.66(s,1H),7.59(s,2H),7.22(d,J＝2.8Hz,1H),7.20-7.15(m,1H),5.24(s,2H),4.77(s,2H).
13CNMR(400MHz,DMSO-d 6)ppm 140.18,138.50,138.39,134.92,131.39,128.43,126.61,126.09,114.33.
中间体化合物III-23000-1的制备
Figure PCTCN2020137979-appb-000096
第一步:N-(4-氨基-5-硝基吡啶-3-基)
向100毫升单口瓶中依次加入5-硝基吡啶-3,4-二胺(2g,13mmol)，吡啶(40mL)，氮气保护下，0℃滴加吡啶甲酰氯盐酸盐(3g,19mmol)，0℃搅拌2h。TLC显示反应完毕，加入正己烷(20mL)，过滤，滤饼用二氯甲烷洗涤，柱色谱纯化(洗脱剂5％甲醇/二氯甲烷)得到黄色固体N-(4-氨基-5-硝基吡啶-3-基)吡啶酰胺(1.5g,收率58％)。
MS(ESI):C 11H 9N 5O 3:259.9[M+1].
第二步:N-(4,5-二氨基吡啶-3-基)吡啶酰胺
向100毫升单口瓶中依次加入N-(4-氨基-5-硝基吡啶-3-基)吡啶酰胺(1.8g,6.9mmol)，甲醇(30mL)，Pd/C(150mg)，通入氢气，反应液室温下搅拌16h。TLC显示反应完毕。过滤，浓缩得到粗品。粗品柱纯化，洗脱剂：二氯甲烷/甲醇(2mL,10:1),干燥得到淡黄色固体N-(4,5-二氨基吡啶-3-基)吡啶酰胺(1.05g,收率65％)。
MS(ESI)C 11H 11N 5O:229.9[M+1].
1HNMR(400MHz,DMSO-d 6)ppm:10.20(s,1H),8.75(d,J＝2.8Hz,1H),8.12(d,J＝7.2Hz,1H),8.06(t,J＝7.2Hz,1H),7.81(s,1H),7.69(m,1H),7.62(s,1H),6.45(s,2H),5.40(s,2H).
13CNMR(400MHz,DMSO-d 6)ppm:164.06,150.18,148.89,141.24,138.31,133.51,132.83,127.34,125.85,122.90,118.53.
中间体化合物III-23000-3的制备
Figure PCTCN2020137979-appb-000097
第一步:5-硝基吡啶-3,4-二胺
向500毫升单口瓶中依次加入3,5-二硝基吡啶-4-胺(20g,0.11mol)，甲醇(150mL)，室温下滴加硫化铵(100mL,20％水溶液)。反应液在室温下搅拌16h，TLC显示反应完毕。加入水(200mL)， 过滤，洗涤滤饼二氯甲烷/甲醇(200mL,10:1),干燥得5-硝基吡啶-3,4-二胺(16g粗品)，棕色固体。
MS(ESI)C 5H 6N 4O 2:154.8[M+1].
1HNMR(400MHz,DMSO-d 6)ppm:8.42(s,1H),7.73(s,1H),7.40(s,2H),5.31(s,2H).
第二步:N-(4-氨基-5-硝基吡啶-3-基)-3-氟苯甲酰胺
向100毫升单口瓶中依次加入5-硝基吡啶-3,4-二胺(2g,13mmol)，吡啶(40mL)，氮气保护下，0℃，滴加3-氟苯甲酰氯(3g,19mmol)，然后0℃搅拌2h，TLC显示反应完毕。加入正己烷(20mL)，过滤，用二氯甲烷洗涤，滤饼用柱纯化，(洗脱剂：5％甲醇/二氯甲烷)，得到N-(4-氨基-5-硝基吡啶-3-基)-3-氟苯甲酰胺(1.5g,收率58％)，淡黄色固体。
MS(ESI)C 12H 9FN 4O 3:277.1[M+1].
第三步:N-(4,5-二氨基吡啶-3-基)-3-氟苯甲酰胺
向100毫升单口瓶中依次加入N-(4-氨基-5-硝基吡啶-3-基)-3-氟苯甲酰胺(1.5g,5.4mmol)，甲醇(30mL)，Pd/C(150mg)，通入氢气，室温下搅拌16h，TLC显示反应完毕。反应液过滤，浓缩滤液得到粗品。粗品用二氯甲烷/甲醇(5mL,10:1)打浆，过滤，二氯甲烷洗涤，干燥得N-(4,5-二氨基吡啶-3-基)-3-氟苯甲酰胺(1.05g,收率78％)，白色固体。
MS(ESI)C 12H 11FN 4O:247.0[M+1]
1HNMR(400MHz,DMSO-d 6)ppm:10.10(s,1H),7.93(s,1H),7.90-7.88(m,2H),7.62-7.57(m,2H),7.50-7.45(dt,J＝8.0,2.0Hz,1H),7.34(s,2H),5.76(s,2H).
13CNMR(101MHz,DMSO-d 6)ppm 165.53&163.5&161.1,145.05,136.59&136.51,133.36,130.87&130.79,130.06,124.92&124.90,119.26,119.03,117.59,115.65&115.42.
中间体化合物IV-23000-5的制备
Figure PCTCN2020137979-appb-000098
第一步:N-(4-氨基-5-硝基吡啶-3-基)-3-氟苯磺酰胺
向500毫升单口瓶中依次加入5-硝基吡啶-3,4-二胺(5g,32.44mmol)，3-氟苯基-1-磺酰氯(6.31g,32.44mmol)，吡啶(150mL)，氮气保护下，室温搅拌3小时。TLC显示反应完毕，反应液浓缩，柱纯化，(洗脱剂：2％-10％乙酸乙酯/正己烷)，得到灰色固体N-(4-氨基-5-硝基吡啶-3-基)-3-氟苯磺酰胺(2.3g,收率23％)。
MS(ESI):C 11H 9FN 4O 4S:313.1[M+1]
第二步:N-(4,5-二氨基吡啶-3-基)-3-氟苯磺酰胺
向100毫升单口瓶中依次加入N-(4-氨基-5-硝基吡啶-3-基)-3-氟苯磺酰胺(2g,7.34mmol)，钯碳(5％)(345mg),甲醇(30mL)，通入氢气，室温搅拌过夜。TLC显示反应完毕。过滤，浓缩滤液， 粗产品用二氯甲烷/甲醇(5mL*2,10/1)洗涤，得到灰色固体N-(4,5-二氨基吡啶-3-基)-3-氟苯磺酰胺(1.1g,收率53％)。
MS(ESI)C 11H 11FN 4O 2S:283.1[M+1]
1HNMR(400MHz,DMSO-d 6)ppm:7.55-7.38(m,6H),6.77(s,2H),5.31-5.36(m,2H)
13CNMR(400MHz,DMSO-d 6)ppm:163.3,160.8,144.0,132.2,131.7&131.8,126.5,123.4,120.4,119.8&120.0,119.0,114.0&114.3.
实施例1化合物I-22001合成
Figure PCTCN2020137979-appb-000099
向100毫升单口瓶依次加入III-22000-A(211mg,0.5mmol，1eq)，IV-22000-6(102mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq),5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体303毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到83毫克灰色固体(纯度97.5％)。
1H NMR(400MHz,DMSO-d 6)ppm:δ14.04(s,1H),13.72(s,1H),10.17(s,1H),8.84(s,1H),8.68(s,1H),8.57(d,J＝2.0Hz,1H),8.23–7.98(m,4H),7.89–7.73(m,2H),7.49–7.31(m,2H),7.20(td,J＝8.6,2.5Hz,1H),2.23–2.07(m,2H),1.99(dt,J＝13.6,6.8Hz,1H),0.85(d,J＝6.6Hz,6H).
MS(ESI)m/z＝522[M+H] +.
实施例2化合物I-22002合成
Figure PCTCN2020137979-appb-000100
向100毫升单口瓶依次加入III-22000-A(211mg,0.5mmol，1eq)，IV-22000-1(102mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体303毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到90毫克灰白色 固体(纯度95.5％)。
1H NMR(400MHz,DMSO-d 6)δ10.53(s,1H),8.83(s,1H),8.66(d,J＝2.0Hz,1H),8.27(s,1H),8.15–7.99(m,2H),7.92–7.69(m,3H),7.46(q,J＝7.1Hz,1H),7.40–7.15(m,3H),2.19(d,J＝7.2Hz,2H),2.01(hept,J＝6.7Hz,1H),0.87(d,J＝6.6Hz,6H)；
MS(ESI)m/z＝522[M+H] +
实施例3化合物I-22003合成
Figure PCTCN2020137979-appb-000101
向100毫升单口瓶依次加入III-22000-B(197mg,0.5mmol,1eq)，IV-22000-6(102mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体289毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L)，搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到100毫克淡黄色固体(纯度92.9％)。
1H NMR(400MHz,DMSO-d 6)δ10.38(s,1H),8.83–7.96(m,7H),7.74(d,J＝10.9Hz,2H),7.53–6.94(m,4H),2.29(q,J＝7.7Hz,2H),0.99(t,J＝7.6Hz,3H)；
MS(ESI)m/z＝494[M+H] +
实施例4化合物I-22004合成
Figure PCTCN2020137979-appb-000102
向100毫升单口瓶依次加入III-22000-A(211mg,0.5mmol，1eq)，IV-22000-2(96mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体297毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到61毫克棕色固体(纯度93.5％)。
1H NMR(400MHz,DMSO-d 6)δppm 14.41(s,1H),10.62(s,1H),9.09 8.72(m,3H),8.27(s,1H),8.06(d,J＝14.5Hz,3H),7.77(ddJ＝45.8 6.6Hz,2H),7.44(d,J＝8.4Hz,1H),7.22(s,1H),2.19(d,J＝6.8Hz,2H),2.10– 1.89(m,1H),0.84(d,J＝6.4Hz,6H)；
MS(ESI)m/z＝510[M+H] +
实施例5化合物I-22010合成
Figure PCTCN2020137979-appb-000103
向100毫升单口瓶依次加入III-22000-A(211mg,0.5mmol，1eq)，IV-23000-1(115mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体316毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克1.25mmol,2.5eq)，三氟乙酸(1.71克15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到61毫克棕色固体(纯度89.6％)。
1HNMR(400MHz,DMSO-d 6)ppm:δ10.82(s,1H),10.16(s,1H),9.06(s,1H),8.69(d,J＝4.7Hz,1H),8.61(s,1H),8.55(d,J＝2.0Hz,1H),8.32(s,1H),8.24(d,J＝7.8Hz,1H),8.19–8.08(m,2H),7.76–7.65(m,3H),7.28(dd,J＝8.9,2.4Hz,1H),2.13(d,J＝7.1Hz,2H),1.99(dt,J＝13.6,6.8Hz,1H),0.85(d,J＝6.6Hz,6H)；
MS(ESI)m/z＝548[M+H] +.
实施例6化合物I-22011合成
Figure PCTCN2020137979-appb-000104
向100毫升单口瓶依次加入III-22000-B(197mg,0.5mmol，1eq)，IV-23000-3(123mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体268毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到65毫克灰色固体,(纯度91.4％)。
1H NMR(400MHz,DMSO-d 6)ppm:δ10.18(s,1H),8.70(d,J＝15.1Hz,2H),8.51(d,J＝2.0Hz,1H),8.17(dd,J＝29.3,2.5Hz,2H),7.95–7.83(m,2H),7.75(d J＝8.9Hz,1H),7.68(t,J＝2.3Hz,1H),7.64–7.55(m,1H), 7.47(td,1H),7.26(dd,J＝8.9,2.4Hz,1H),2.27(t,J＝7.5Hz,2H),1.00(t,J＝7.5Hz,3H)；
MS(ESI)m/z＝537[M+H] +.
实施例7化合物I-22012合成
Figure PCTCN2020137979-appb-000105
向100毫升单口瓶依次加入III-22000-B(197mg,0.5mmol，1eq)，IV-23000-5(141mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体286毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到100毫克褐色固体(纯度90.4％)。
1HNMR(400MHz,DMSO-d 6)δ14.05(s,1H),10.18(s,1H),8.56(d,J＝48.7Hz,2H),8.30–7.96(m,3H),7.86–7.55(m,4H),7.53–7.21(m,3H),2.29(q,J＝7.5Hz,2H),1.00(t,J＝7.5Hz,3H)；
MS(ESI)m/z＝573[M+H] +.
实施例8化合物I-23001合成
Figure PCTCN2020137979-appb-000106
向100毫升单口瓶依次加入III-22000-C(203mg,0.5mmol，1eq)，IV-23000-1(114.5mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体300毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到50毫克棕色固体(纯度97.50％)。
MS(ESI)m/z＝532.2[M+H] +.
1HNMR(400MHz,DMSO-d 6)ppm：14.10(s,1H),13.80(s,1H),11.10(s,1H),10.23(s,1H),9.42-7.72(m,12H),2.24(d,2H),2.10(m,1H),0.95(dd,6H)。
实施例9化合物I-23002合成
Figure PCTCN2020137979-appb-000107
向100毫升单口瓶依次加入III-22000-C(203mg,0.5mmol，1eq)，IV-23000-2(114.5mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体320毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到80毫克棕色固体(纯度94.17％)。
MS(ESI)m/z＝532.2[M+H] +.
1HNMR(400MHz,DMSO-d 6)ppm:14.10(s,1H),13.80(s,1H),11.10(s,1H),10.23(s,1H),9.42-7.72(m,12H),2.24(d,2H),2.10(m,1H),0.95(dd,6H)。
实施例10化合物I-23003合成
Figure PCTCN2020137979-appb-000108
向100毫升单口瓶依次加入III-22000-C(165mg,0.4mmol，1eq)，IV-23000-3(100mg,0.4mmol,1eq)，亚硫酸钠(126mg,0.44mmol,1.1eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体260毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,3eq)，三氟乙酸(1.71克，15mmol,37eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到40毫克棕色固体(纯度94.17％)。
MS(ESI)m/z＝549.3[M+H] +.
1HNMR(400MHz,DMSO-d 6)ppm：14.50(s,1H),14.27(s,1H),10.90(s,1H),10.38(s,1H),9.92-7.48(m,12H),2.35(d,2H),2.13(m,1H),0.92(dd,6H)。
实施例11化合物I-23005合成
Figure PCTCN2020137979-appb-000109
向100毫升单口瓶依次加入III-22000-C(203mg,0.5mmol，1eq)，IV-23000-5(141mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体334毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到73毫克棕色固体(纯度80％)。
1HNMR(400MHz,DMSO-d 6)δ13.98(s,1H),10.24(s,1H),8.96–7.00(m,13H),2.39–2.02(m,3H),0.97(d,J＝6.6Hz,6H)；
MS(ESI)m/z＝585[M+H] +。
实施例12化合物I-24001合成
Figure PCTCN2020137979-appb-000110
向100毫升单口瓶依次加入III-24000-A(225mg,0.5mmol，1eq)，IV-22000-1(102mg,0.5mmol,1eq)，焦亚硫酸钠(190mg,1mmol,2eq)，5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出固体316毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到67毫克白色固体(纯度94％)。
1H NMR(400MHz,DMSO-d 6)δ10.63(s,1H),10.15(s,1H),9.19(s,1H),8.86(s,1H),8.69(d,J＝2.2Hz,1H),8.65–8.51(m,3H),8.24(d,J＝1.9Hz,1H),8.11(s,1H),7.94(d,J＝8.5Hz,1H),7.71(d,J＝8.7Hz,1H),7.48–7.24(m,4H),2.15–2.01(m,2H),0.97(d,J＝6.6Hz,6H)；
MS(ESI)m/z＝549[M+H] +
实施例13化合物I-24002合成
Figure PCTCN2020137979-appb-000111
向100毫升单口瓶依次加入III-24000-B(220mg,0.49mmol 1eq)，IV-22000-1(100mg,0.49mmol,1eq)，焦亚硫酸(187mg,0.98mmol,2eq)，6毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出灰色固体310毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到60毫克棕色固体(纯度98.13％)。
MS(ESI)m/z＝549.2[M+H] +.
1HNMR(400MHz,DMSO-d 6)ppm：13.70(s,1H),13.27(s,1H),10.60(s,1H),10.35(s,1H),9.12-7.65(m,12H),2.24(d,2H),2.13(m,1H),0.97(dd,6H)。
实施例14化合物I-24009合成
Figure PCTCN2020137979-appb-000112
向100毫升单口瓶依次加入III-24000-B(220mg,0.5mmol，1eq),IV-22000-6(102mg,0.5mmol,1eq),焦亚硫酸钠(191mg,1mmol,2eq),5毫升N-甲基吡咯烷酮，氮气保护下，100℃磁力搅拌过夜。冷却至室温，加入20毫升水，搅拌1h，析出灰色固体320毫克。
将上述固体转移至100毫升单口瓶中，依次加入二氯甲烷(10毫升)，三乙基硅烷(0.15克，1.25mmol,2.5eq)，三氟乙酸(1.71克，15mmol,30eq)，室温搅拌过夜。减压浓缩，加入10毫升氨水(5mol/L),搅拌，析出固体，柱色谱纯化(洗脱剂：二氯甲烷/甲醇＝20:1-10:1)，得到120毫克棕色固体(纯度98.20％)。
MS(ESI)m/z＝549.2[M+H] +.
1HNMR(400MHz,DMSO-d 6)ppm：13.85(s,1H),13.22(s,1H),10.70(s,1H),10.38(s,1H),9.20-7.20(m,12H),2.25(d,2H),2.10(m,1H),0.98(dd,6H)。
实施例15化合物I-25003合成
Figure PCTCN2020137979-appb-000113
中间体3-2：
将原料3-1(20g，0.1mol)、丙酮(450mL)加入到1L三口瓶中，冰盐浴降温至0℃下，滴加亚硝酸钠水溶液(55.2g，8eq溶于100mL水)，保持温度不超过0℃。再滴加稀盐酸(2NHCl，240mL)。随后升温至室温下反应4h。旋干，加入乙酸乙酯萃取(100mL×2)，合并有机层，旋干得粗品。粗品经二氯甲烷打浆得中间体3-2，棕红色固体，收率90％。
中间体3-3：
R 2q＝THP：中间体3-2加入到250mL三口瓶中，加入四氢呋喃(180mL)、对甲基苯磺酸(0.690.1eq)，室温下滴加3,4-二氢吡喃(6.72g，2eq)，并在40℃下反应8h。随后减压蒸除溶剂，经硅胶柱层析纯化得中间体3-3(THP)粗品，经PE打浆后得白色固体，收率32％。
中间体3-4(硼酸酯化)：
将中间体3-3(THP,3.1g,10mmol)加入到100mL单口瓶中，加入联硼酸频那醇酯(3.0g，1.2eq)、乙酸钾(2.94g，3eq)、Pd(dppf)Cl 2(0.36g,0.05eq)、二氧六环(26mL)。升温至回流反应6h，降温后抽滤、旋干、经硅胶柱层析纯化的中间体3-4，白色固体，收率90％。
中间体4-1：
将中间体3-4(THP，1.07g，3mmol)、中间体2-2(异戊酸，0.93g，1.2eq)、碳酸钠(0.95g，3eq)、Pd(dppf)Cl 2(0.1g,0.05eq)、二氧六环(9mL)、水(1.5mL)加入到50mL单口瓶中，氮气置换空气，升温至回流下反应8h。降温后抽滤、旋干、经硅胶柱层析纯化得到中间体4-1，黄色油状物，收率69％。其他取代基操作同上。
将中间体4-1(R 1＝i-Bu，R 2＝CH 3，0.18g，0.5mmol)、中间体1-5c(1eq)加入到50mL单口瓶中，加入焦亚硫酸钠(0.14g，1.5eq)、DMF(5mL)，120℃下反应6h。降温后加水淬灭，抽滤、水洗得得到粗品。再经脱保护(TFA:10eq，Et 3SiH:2.5eq，DCM)得白色固体。
11HNMR(DMSO-d 6,300MHz):ppm.δ＝14.4(s,1H),10.76(s,1H),9.91(s,1H),9.13(s,1H),8.98(s,1H),8.95(s,1H),8.81(s,1H),8.73(s,1H),8.34(d,J＝8.37Hz,1H),8.10–7.90(m,4H),7.51(d,J＝7.9Hz,4H),7.12(d,J＝7.9Hz,4H),2.35(d,J＝7.1Hz,2H),2.27(s,6H),2.20–2.11(m,1H),1.00(d,J＝6.6Hz,6H)
MS(ESI)m/z＝462.2[M+H] +.
实施例16化合物I-25007合成
Figure PCTCN2020137979-appb-000114
实验操作过程
中间体3-1:
将Boc-哌啶酮(10g,50.19mmol,1eq)溶于100mL乙醇中,加入盐酸羟胺(6.97g,100.38mmol,2eq)和乙酸钠(8.23g,100.38mmol,2eq),回流反应8小时。
后处理：抽滤，弃去滤饼，滤液浓缩后，溶于乙酸乙酯，用饱和碳酸氢钠水溶液和饱和食盐水洗涤一次，旋干有机相，得白色固体，收率91％
中间体3-2：
将3-1(9g,42mmol,1eq)溶于90mL二氯甲烷中，加入三乙胺(4.67g,46.2mmol,1.1eq)，降温至0℃，加入对甲苯磺酰氯(7.95g,46.2mmol,1.1eq)，于室温下反应8小时。
后处理：向反应液中加入饱和食盐水，分液，有机相旋干，得白色固体，收率71％
中间体3-3：
将无水硫酸镁(3.92g,32.5mmol,6eq)溶于无水乙醇中，加入乙醇钾(0.91g,10.8mmol,2eq)，降温至0℃，分批加入3-2(2g,5.43mmol,1eq)，加入完毕后升温至回流，反应12小时。
后处理：抽滤，弃去滤饼，滤液旋干，得淡黄色油状物，不做纯化处理。
MS(ESI)m/z＝289.20[M+H] +.
中间体3-4、3-5和3-6合成见上文描述。
中间体3-7：
将中间体3-6(0.58g,1.62mmol,1eq)，3-溴吡啶(0.28g,1.79mmol,1.1eq)，碳酸钠(0.52g,4.88mmol,2eq)，PdCl 2(dppf)(0.06g,0.08mmol,0.05eq)和6mL二氧六环/水(6:1)混合搅拌，氮气保护，反应液升温至100℃，搅拌过夜。
后处理：抽滤，滤液旋干，柱层析，得白色固体，收率83％。
MS(ESI)m/z＝308.40[M+H] +.
中间体3-8：:
将3-7(0.42g,1.36mmol,1eq)溶于8mL乙腈中，加入三乙胺(0.34g,3.41mmol,2.5eq)和盐酸羟胺(0.14g,2.05mmol,1.5eq)，将反应液升温至60℃反应3小时后，将反应液降温至0℃，加入三乙胺(1.1g,10.9mmol,8eq)和三氟乙酸酐(1.14g,5.46mmol,4eq)，滴加完毕后，于室温下反应5小时。
后处理：反应液中加冰水，有固体析出，抽滤，滤饼干燥得黄色固体，收率86％。
MS(ESI)m/z＝305.40[M+H] +.
中间体3-9：
将3-8(0.36g,1.18mmol,1eq)溶于6mL甲醇中，加入甲醇钠(0.2g,3.55mmol,3eq)，于室温下反应。
后处理：将反应液旋干，加入乙酸乙酯，用饱和食盐水洗涤后，旋干有机相，得淡黄色固体，不做纯化处理。
中间体3-10：
将3-9(0.96g,2.85mmol,1eq)溶于20mL乙醇中,加入中间体3-3(1.07g,3.7mmol,1.05eq)和乙酸(0.33mL,5.714mmol,2eq),将反应液升温至50℃反应。
后处理：将反应液旋干,得黄色色油状物,不做纯化处理。
中间体3-11：
将中间体3-10(0.62g,1.04mmol,1eq)溶于3mL乙醇中，加入浓盐酸(0.71mL,22.88mmol,22eq)，将反应液升温至50℃反应8小时。
后处理：抽滤，滤饼干燥，得淡黄色固体，不做纯化处理。
MS(ESI)m/z＝401.50[M+H] +.
I-25007：
将中间体3-11(0.1g,0.249mmol,1eq)溶于2mLDMF中，加入HATU(0.14g,0.374mmol,1.5eq)、DIPEA(0.07g,0.549mmol,2.2eq)和4-氟苯甲酸(0.042g,0.3mmol,1.2eq)，室温下搅拌8小时。
后处理：向反应液中加入10毫升冰水，用30毫升乙酸乙酯萃取，合并有机相，浓缩得黄色油状物，不做纯化处理。
MS(ESI)m/z＝519.70[M+H] +.
将上述中间体(0.26g,0.497mmol,1eq)溶于4mL二氯甲烷中，加入三乙基硅烷(0.2mL,1.24mmol,2.5eq)和三氟乙酸(0.37mL,4.97mmol,10eq)，回流15小时。
后处理：浓缩干反应液，柱层析(洗脱剂：DCM/MeOH＝50:1-20:1)，得类白色固体70毫克。
MS(ESI)m/z＝439.2[M+H] +.
1H NMR(DMSO-d 6,300MHz):ppm：14.10(s,1H),9.08(s,1H),8.70-8.10(m,4H),7.90-7.33(m,8H),7.22(m,4H),4.75(m,2H),3.80(m,2H),2.93(m,2H)。
实施例17化合物I-25008合成
将中间体3-11(0.1g,0.249mmol,1eq)溶于2mLDMF中，加入HATU(0.14g,0.374mmol,1.5eq)、 DIPEA(0.07g,0.549mmol 2.2eq)和4-氰基苯甲酸(0.044g,0.3mmol,1.2eq)，室温下搅拌8小时。
后处理：向反应液中加入10毫升冰水，用30毫升乙酸乙酯萃取，合并有机相，浓缩得黄色油状物，不做纯化处理。
MS(ESI)m/z＝519.70[M+H] +.
将上述中间体(0.27g,0.5mmol,1eq)溶于4mL二氯甲烷中，加入三乙基硅烷(0.2mL,1.24mmol,2.5eq)和三氟乙酸(0.38mL,5mmol,10eq)，回流15小时。
后处理：浓缩干反应液，柱层析(洗脱剂：DCM/MeOH＝50:1-20:1)，得类白色固体80毫克。
MS(ESI)m/z＝446.2[M+H] +.
1HNMR(DMSO-d 6,300MHz):ppm：14.11(s,1H),9.10(s,1H),8.62(m,2H),8.22(s,1H),7.90-7.60(m,7H),4.90-4.50(m,2H),3.95-3.52(m,2H),2.90(m,2H)。
实施例18化合物I-25009合成
将中间体3-11(0.1g,0.249mmol,1eq)溶于2mLDMF中，加入HATU(0.14g,0.374mmol,1.5eq)、DIPEA(0.07g,0.549mmol,2.2eq)和4-甲苯甲酸(0.04g,0.299mmol,1.2eq)，室温下搅拌8小时。
后处理：向反应液中加入10毫升冰水，用30毫升乙酸乙酯萃取，合并有机相，浓缩得黄色油状物，不做纯化处理。
MS(ESI)m/z＝519.70[M+H] +.
将上述中间体(0.26g,0.5mmol,1eq)溶于4mL二氯甲烷中，加入三乙基硅烷(0.2mL,1.24mmol,2.5eq)和三氟乙酸(0.38mL,5mmol,10eq)，回流15小时。
后处理：浓缩干反应液，柱层析(洗脱剂：DCM/MeOH＝50:1-20:1)，得类白色固体80毫克。
MS(ES +):435.4(ES -)：433.2.
1H NMR(DMSO-d 6,300MHz)ppm：14.07(s,1H),9.08(s,1H),8.62(s,2H),8.15(s,1H),7.80(m,2H),7.52(m,1H),7.40-7.22(m,4H),4.60(m,2H),3.72(m,2H),2.88(m,2H),2.28(s,3H).
实施例19化合物I-25010合成
将中间体3-11(0.1g,0.249mmol,1eq)溶于2mLDMF中，加入HATU(0.14g,0.374mmol,1.5eq)、DIPEA(0.07g,0.549mmol,2.2eq)和3-溴苯乙酸(0.065g,0.3mmol,1.2eq)，室温下搅拌8小时。
后处理：向反应液中加入10毫升冰水，用30毫升乙酸乙酯萃取，合并有机相，浓缩得黄色油状物，不做纯化处理。
MS(ESI)m/z＝519.70[M+H] +.
将上述中间体(0.30g,0.5mmol,1eq)溶于4mL二氯甲烷中，加入三乙基硅烷(0.2mL,1.24mmol,2.5eq)和三氟乙酸(0.38mL,5mmol,10eq)，回流15小时。
后处理：浓缩干反应液，柱层析(洗脱剂：DCM/MeOH＝50:1-20:1)，得类白色固体60毫克。
MS(ESI)m/z＝515.1[M+H] +.
1H NMR(DMSO,300MHz)ppm：14.15(s,1H),9.08(s,1H),8.72(m,2H),8.20(s,1H),7.90-7.32(m,7H),4.780(m,2H),3.95(m,4H),2.80(m,2H).
效果实施例
人源性滑膜干细胞体外成软骨和成骨诱导分化实验
将人源性滑膜间充质干细胞(SMSC)接种到六孔板的每个孔，5％CO 2，37℃培养至每孔细胞密度达到95％。以10μM的终浓度像细胞中加入化合物(在DMSO溶液中)，并在5％CO 2，37℃下培养细胞21天。Trizol法提取RNA，逆转录成cDNA。检测成软骨基因蛋白多糖(Aggrecan)、Ⅱ型胶原(Collagen II)和sox9，和成骨基因Ⅰ型胶原(collagen Ⅰ)、Ⅹ型胶原(collagen Ⅹ)、成骨转录基因(RUNX2)、碱性磷酸酶(ALP)等的基因表达在细胞内的相对表达量。相对表达量使用LightCycler 480 II系统检测(Roche)。使用载体(DMSO)作为对照来确定软骨成骨细胞分化的基础水平。本实验中待测的目的基因为Aggrecan、Collagen II、sox9、Collagen Ⅰ、Collagen Ⅹ、RUNX2、和ALP等基因，内参基因为GAPDH。其中Aggrecan、Collagen II、sox9三个基因为成软骨基因，Ⅰ型胶原(collagen Ⅰ)、和Ⅹ型胶原(collagen Ⅹ)、成骨转录基因(RUNX2)、碱性磷酸酶(ALP)为成骨基因，sox2是一种转录因子，是诱导干细胞的标志。具体结果如表1：
表1
Figure PCTCN2020137979-appb-000115
其中，表中化合物编号为SM04690的结构式为
Figure PCTCN2020137979-appb-000116
备注：A～D分别代表不同活性级别，具体见下表2：
活性级别 A B C D
mAGGRECAN 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
mCOL2A1 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
SOX9 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
COL1 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
COL10 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
RUNX2 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
ALP 0-1.0 1.0-3.0 3.0-5.0 5.0-10.0
由上表1可知，在本申请化合物的诱导下，Ⅱ型胶原、sox9基因、collagen Ⅰ、Ⅹ型胶原、成骨转录基因(RUNX2)和碱性磷酸酶中的一种或多种的表达量升高。
可见，在本申请的化合物的诱导下，滑膜间充质干细胞向成软骨和/或成骨细胞进行分化，可用于治疗或预防关节炎、关节损伤、成骨再生、骨质疏松症和骨肿瘤中的一种或多种疾病。

Claims (18)

  1. 一种如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药：
    Figure PCTCN2020137979-appb-100001
    其中，R 1a和R 1b独立地为H或
    Figure PCTCN2020137979-appb-100002
    但R 1a和R 1b不同时为H；
    或者，R 1a和R 1b与其相连碳的原子一起形成C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
    所述的C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环和R 1b-2取代的C 3～C 10的杂芳环中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
    A为O或C 1～C 4的亚烷基；
    R 1b-1和R 1b-2独立地为
    Figure PCTCN2020137979-appb-100003
    Z和Z'独立地为直键、O、
    Figure PCTCN2020137979-appb-100004
    且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
    Q为直键或C 1～C 4的亚烷基；
    R 1a-1独立地为C 6～C 18的芳基、R 1a-1-1取代的C 6～C 18的芳基、C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基；所述的C 3～C 10的杂芳基和R 1a-1-2取代的C 3～C 10的杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
    R 1a-1-1和R 1a-1-2独立地为卤素、C 1～C 4的烷基或氰基；
    R 2为C 6～C 18的芳基、R 2-1取代的C 6～C 18的芳基、C 3～C 10杂芳基或R 2-2取代的C 3～C 10杂芳基，所述的C 3～C 10杂芳基和R 2-2取代的C 3～C 10杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
    R 2-1和R 2-2独立地为
    Figure PCTCN2020137979-appb-100005
    氨基或
    Figure PCTCN2020137979-appb-100006
    R 2-1-1为C 1～C 4的烷基或C 3～C 6的环烷基；
    所述的R 1b-1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2的个数独立地为一个或多个；当所述的R 1b-1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2独立地为多个时，所述的R 1b- 1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2独立地相同或不同。
  2. 如权利要求1所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，当Z'为
    Figure PCTCN2020137979-appb-100007
    时，其N端与A相连，C端与R 1-a相连；
    和/或，当Z'为
    Figure PCTCN2020137979-appb-100008
    时，其N端与A相连，S端与R 1-a相连；
    和/或，当Z'为
    Figure PCTCN2020137979-appb-100009
    时，其C端与A相连，Q端与R 1-a相连；
    和/或，Z和Z'不同时为直键；
    和/或，当Q为C 1～C 4的亚烷基时，所述的C 1～C 4的亚烷基为亚甲基、亚乙基、亚正丙基、亚异丙基、亚正丁基、
    Figure PCTCN2020137979-appb-100010
    或亚叔丁基，可以为亚甲基；
    和/或，当R 1a-1为C 6～C 18的芳基或R 1a-1-1取代的C 6～C 18的芳基时，所述的C 6～C 18的芳基为C 6～C 14的芳基，进一步可以为苯基；
    和/或，当R 1a-1为R 1a-1-1取代的C 6～C 18的芳基时，所述的R 1a-1-1位于所述Z'的邻位或间位；
    和/或，当R 1a-1为R 1a-1-1取代的C 6～C 18的芳基时，所述R 1a-1-1的个数为1个；
    和/或，当R 1a-1-1为卤素时，所述的卤素为F、Cl、Br或I，还可以为F；
    和/或，当R 1a-1为C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基时，所述的C 3～C 10的杂芳基中杂原子为N或S，个数为1个；
    和/或，当R 1a-1为C 3～C 10的杂芳基或R 1a-1-2取代的C 3～C 10的杂芳基时，所述的C 3～C 10的杂芳基为C 3～C 5的杂芳基；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环时，所述的C 3～C 10的杂环中的杂原子为N，个数为1个；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环，所述的C 3～C 10的杂环为C 3～C 5的杂环烷基；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环时，所述的C 3～C 10的杂环通过杂原子与Z'相连接；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环 时，所述的C 3～C 10的杂芳环中的杂原子为N，个数为1个；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环为C 3～C 9的杂芳环；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环为通过C原子与Z'相连接；
    和/或，当R 1a-1-1为卤素时，所述的卤素为F、Cl、Br或I，还可以为F；
    和/或，当R 2为C 2～C 10的杂芳基或R 2-2取代的C 2～C 10杂芳基时，所述的C 2～C 10的杂芳基中的杂原子为N，个数为1个；
    和/或，当R 2为C 3～C 10的杂芳基或R 2-2取代的C 3～C 10杂芳基时，所述的C 3～C 10的杂芳基为C 3～C 5的杂芳基；
    和/或，当R 2为R 2-2取代的C 2～C 10杂芳基时，所述的R 2-2的个数为一个；
    和/或，当R 2-2为
    Figure PCTCN2020137979-appb-100011
    所述的R 2-1-1为C 1～C 4的烷基时，所述的C 1～C 4的烷基为甲基、乙基、正丙基、异丙基、正丁基、
    Figure PCTCN2020137979-appb-100012
    或叔丁基，可以为乙基或
    Figure PCTCN2020137979-appb-100013
    可以为
    Figure PCTCN2020137979-appb-100014
  3. 如权利要求2所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，当R 1a-1为R 1a- 1-1取代的C 6～C 18的芳基时，所述的R 1a-1-1取代的C 6～C 18的芳基为卤素取代的C 6～C 14的芳基，进一步可为
    Figure PCTCN2020137979-appb-100015
    更进一步可为
    Figure PCTCN2020137979-appb-100016
    和/或，当R 1a-1为C 3～C 10的杂芳基时，所述的C 3～C 10的杂芳基为C 3～C 5的杂芳基、杂原子为N、个数为1个，进一步可为吡啶基或噻吩基，更进一步可为
    Figure PCTCN2020137979-appb-100017
    更进一步还可为
    Figure PCTCN2020137979-appb-100018
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环或R 1b-1取代的C 3～C 10的杂环时，所述的C 3～C 10的杂环为C 3～C 5的杂环、杂原子为N、杂原子个数为1个，进一步可以为哌啶环；
    和/或，所述的
    Figure PCTCN2020137979-appb-100019
    为
    Figure PCTCN2020137979-appb-100020
    Figure PCTCN2020137979-appb-100021
    和/或，当R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环时，所述的C 3～C 10的杂芳环为C 3～C 9的杂芳环、杂原子为N、杂原子个数为1个，进一步可以为吡啶环或喹啉环；
    和/或，R 2为R 2-2取代的C 3～C 10的杂芳基时，所述的R 2-2取代的C 3～C 10的杂芳基为
    Figure PCTCN2020137979-appb-100022
  4. 如权利要求3所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，所述的R 1b-1取代的C 3～C 10的杂环为
    Figure PCTCN2020137979-appb-100023
    还可以为
    Figure PCTCN2020137979-appb-100024
    Figure PCTCN2020137979-appb-100025
    其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用；
    和/或，当R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环时，所述的R 1b-2取 代的C 3～C 10的杂芳环为
    Figure PCTCN2020137979-appb-100026
    Figure PCTCN2020137979-appb-100027
    还可以为
    Figure PCTCN2020137979-appb-100028
    Figure PCTCN2020137979-appb-100029
    Figure PCTCN2020137979-appb-100030
    其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用；
    和/或，所述的
    Figure PCTCN2020137979-appb-100031
    为
    Figure PCTCN2020137979-appb-100032
    Figure PCTCN2020137979-appb-100033
  5. 如权利要求1～4中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
    R 1b-1和R 1b-2独立地为
    Figure PCTCN2020137979-appb-100034
    Z为直键、O或
    Figure PCTCN2020137979-appb-100035
    Z'为直键、
    Figure PCTCN2020137979-appb-100036
    且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
    R 1a-1-1为卤素；
    R 2-1和R 2-2独立地为
    Figure PCTCN2020137979-appb-100037
  6. 如权利要求1～5中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，
    R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
    R 1b-1和R 1b-2独立地为
    Figure PCTCN2020137979-appb-100038
    Z为直键、O或
    Figure PCTCN2020137979-appb-100039
    Z'为直键、
    Figure PCTCN2020137979-appb-100040
    且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
    R 1a-1为R 1a-1-1取代的C 6～C 18的芳基或C 3～C 10的杂芳基；
    R 1a-1-1为卤素；
    R 2为C 3～C 10杂芳基或R 2-2取代的C 3～C 10杂芳基；
    R 2-2独立地为
    Figure PCTCN2020137979-appb-100041
    R 2-1-1为C 1～C 4的烷基。
  7. 如权利要求1～6中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，Z为直键、O或
    Figure PCTCN2020137979-appb-100042
    和/或，Z'为直键、
    Figure PCTCN2020137979-appb-100043
    优选
    Figure PCTCN2020137979-appb-100044
    和/或，R 1a-1为C 6～C 18的芳基、R 1a-1-1取代的C 6～C 18的芳基、C 3～C 10的杂芳基、R 1a-1-2取代的C 3～C 10的杂芳基或C 3～C 10的杂环烷基；所述的C 3～C 10的杂芳基和R 1a-1-2取代的C 3～C 10的杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；所述的C 3～C 10的杂环烷基中选自N、O和S中的一种或多种，杂原子数为1～4，优选为R 1a-1-1取代的C 6～C 18的芳基；
    和/或，R 1a-1-2为卤素或C 1～C 4的烷基。
  8. 如权利要求1～7中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，所述的R 1b-1取代的C 3～C 10的杂环为
    Figure PCTCN2020137979-appb-100045
    Figure PCTCN2020137979-appb-100046
    其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用；和，
    Figure PCTCN2020137979-appb-100047
    为
    Figure PCTCN2020137979-appb-100048
    和/或，所述的R 1b-2取代的C 3～C 10的杂芳环为
    Figure PCTCN2020137979-appb-100049
    Figure PCTCN2020137979-appb-100050
    其中，用“*”标记的两个碳之间的化学键和式I中的咪唑环共用；和，
    Figure PCTCN2020137979-appb-100051
    为
    Figure PCTCN2020137979-appb-100052
    Figure PCTCN2020137979-appb-100053
  9. 如权利要求1～8中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，Z为O；
    或，Z为
    Figure PCTCN2020137979-appb-100054
    或，Z'为
    Figure PCTCN2020137979-appb-100055
    或，Z'为
    Figure PCTCN2020137979-appb-100056
    或，Z'为
    Figure PCTCN2020137979-appb-100057
    或，R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环。
  10. 如权利要求1～9中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在于，其为如下任一方案：
    方案1：
    R 1a和R 1b独立地为H或
    Figure PCTCN2020137979-appb-100058
    但R 1a和R 1b不同时为H；
    或者，R 1a和R 1b与其相连碳的原子一起形成C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；
    所述的C 3～C 10的杂环、R 1b-1取代的C 3～C 10的杂环、C 3～C 10的杂芳环和R 1b-2取代的C 3～C 10的杂芳环中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
    A为O或C 1～C 4的亚烷基；
    R 1b-1和R 1b-2独立地为
    Figure PCTCN2020137979-appb-100059
    Z和Z'独立地为直键、O、
    Figure PCTCN2020137979-appb-100060
    且当R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环时，Z和Z'不同时为直键；
    Q为直键或C 1～C 4的亚烷基；
    R 1a-1独立地为C 6～C 18的芳基、R 1a-1-1取代的C 6～C 18的芳基、C 3～C 10的杂芳基、R 1a-1-2取代的C 3～C 10的杂芳基或C 3～C 10的杂环烷基；所述的C 3～C 10的杂芳基和R 1a-1-2取代的C 3～C 10的杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；所述的C 3～C 10的杂环烷基中选自N、O和S中的一种或多种，杂原子数为1～4；
    R 1a-1-1和R 1a-1-2独立地为卤素、C 1～C 4的烷基或氰基；
    R 2为C 6～C 18的芳基、R 2-1取代的C 6～C 18的芳基、C 3～C 10杂芳基或R 2-2取代的C 3～C 10杂芳基，所述的C 3～C 10杂芳基和R 2-2取代的C 3～C 10杂芳基中的杂原子独立地选自N、O和S中的一种或多种，杂原子数为1～4；
    R 2-1和R 2-2独立地为
    Figure PCTCN2020137979-appb-100061
    氨基或
    Figure PCTCN2020137979-appb-100062
    R 2-1-1为C 1～C 4的烷基或C 3～C 6的环烷基；
    所述的R 1b-1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2的个数独立地为一个或多个；当所述的R 1b-1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2独立地为多个时，所述的R 1b- 1、所述的R 1b-2、R 1a-1-1、R 1a-1-2、所述的R 2-1和所述的R 2-2独立地相同或不同；
    方案2：
    R 1a和R 1b与其相连的碳原子一起形成C 3～C 10的杂芳环或R 1b-2取代的C 3～C 10的杂芳环；R 1b-2为
    Figure PCTCN2020137979-appb-100063
    R 1a-1为R 1a-1-1取代的C 6～C 18的芳基或C 3～C 10的杂芳基；R 1a-1-1为卤素；Z为O；Z'独立地为直键、O、
    Figure PCTCN2020137979-appb-100064
    R 2为R 2-2取代的C 3～C 10杂芳基；R 2-2独立地为
    Figure PCTCN2020137979-appb-100065
    和R 2- 1-1为C 1～C 4的烷基；
    方案3：
    R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环；R 1b-2为
    Figure PCTCN2020137979-appb-100066
    R 1a-1为R 1a- 1-1取代的C 6～C 18的芳基；R 1a-1-1为卤素；Z为
    Figure PCTCN2020137979-appb-100067
    Z'为直键；R 2为R 2-2取代的C 3～C 10杂芳基；R 2-2独立地为
    Figure PCTCN2020137979-appb-100068
    和R 2-1-1为C 1～C 4的烷基；
    方案3：
    R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环；R 1b-2为
    Figure PCTCN2020137979-appb-100069
    R 1a-1为R 1a- 1-1取代的C 6～C 18的芳基或C 3～C 10的杂芳基；R 1a-1-1为卤素；Z'为
    Figure PCTCN2020137979-appb-100070
    Z为直键或O；R 2为R 2-2取代的C 3～C 10杂芳基；R 2-2独立地为
    Figure PCTCN2020137979-appb-100071
    和R 2-1-1为C 1～C 4的烷基；
    方案5：
    R 1a和R 1b与其相连的碳原子一起形成R 1b-2取代的C 3～C 10的杂芳环；R 1b-2为
    Figure PCTCN2020137979-appb-100072
    R 1a-1为R 1a- 1-1取代的C 6～C 18的芳基；R 1a-1-1为卤素；Z为直键或O；Z'为
    Figure PCTCN2020137979-appb-100073
    R 2为R 2-2取代的C 3～C 10杂芳基；R 2-2独立地为
    Figure PCTCN2020137979-appb-100074
    和R 2-1-1为C 1～C 4的烷基；
    方案6：
    R 1a和R 1b与其相连的碳原子一起形成R 1b-1取代的C 3～C 10的杂环；R 1b-1为
    Figure PCTCN2020137979-appb-100075
    R 1a-1为R 1a-1- 1取代的C 6～C 18的芳基；R 1a-1-1独立地为卤素、C 1～C 4的烷基或氰基；Z'为
    Figure PCTCN2020137979-appb-100076
    Z为直键；和R 2为C 3～C 10杂芳基。
  11. 如权利要求1～10中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，其特征在 于，
    Figure PCTCN2020137979-appb-100077
    Figure PCTCN2020137979-appb-100078
    Figure PCTCN2020137979-appb-100079
    Figure PCTCN2020137979-appb-100080
  12. 如权利要求1～11中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药的制备方法，其特征在于，其包括以下步骤：溶剂中，在脱保护试剂存在下，将如式II所示的化合物进行如下式的脱保护反应，得到所述的如式I所示的苯并吡唑类化合物即可；
    Figure PCTCN2020137979-appb-100081
    其中，R 3为氨基保护基；R 1a、R 1b、R 2和Z的定义均如权利要求1～11中至少一项所述。
  13. 一种如式II所示的化合物，
    Figure PCTCN2020137979-appb-100082
    其中，R 3为氨基保护基；R 1a、R 1b、R 2和Z的定义均如权利要求1～11中至少一项所述。
  14. 如权利要求13所述的如式II所示的化合物，其特征在于，所述的式II所示的化合物为如下任一化合物：
    Figure PCTCN2020137979-appb-100083
    Figure PCTCN2020137979-appb-100084
  15. 一种药物组合物，其包括如权利要求1～11中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药，和药用辅料。
  16. 一种如权利要求1～11中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或如权利要求15所述的药物组合物在制备药物中的应用。
  17. 一种如权利要求1～11中至少一项所述的如式I所示的苯并吡唑类化合物、其药学上可接受的盐、其水合物、其溶剂化物、其多晶型、其代谢产物、其立体异构体、其互变异构体或其前药、或如权利要求15所述的药物组合物在制备诱导剂中的应用；
    或者，在制备Wnt途径中一种或多种蛋白的抑制剂中的应用。
  18. 如权利按要求17所述的应用，其特征在于，所述的诱导剂为药物；所述的药物用于骨建造剂、或、治疗或预防牙周病、牙周病、关节炎、关节损伤、软骨修复、成骨再生、骨质疏松症、骨质减少、脊柱融合和骨肿瘤中的一种或多种疾病；
    和/或，所述的与Wnt途径中一种或多种蛋白相关的疾病为癌症、与血管生成异常相疾病、细胞增殖和细胞周期相关的疾病、或、Wnt信号传导组分中的一种或多种的变异或失调造成的疾病。
PCT/CN2020/137979 2019-12-20 2020-12-21 苯并吡唑类化合物及其中间体、制备方法和应用 WO2021121420A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019126826 2019-12-20
CNPCT/CN2019/126826 2019-12-20

Publications (1)

Publication Number Publication Date
WO2021121420A1 true WO2021121420A1 (zh) 2021-06-24

Family

ID=76477106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/137979 WO2021121420A1 (zh) 2019-12-20 2020-12-21 苯并吡唑类化合物及其中间体、制备方法和应用

Country Status (1)

Country Link
WO (1) WO2021121420A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CN102595900A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
WO2013151708A1 (en) * 2012-04-04 2013-10-10 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2016040182A1 (en) * 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) * 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CN102595900A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
WO2013151708A1 (en) * 2012-04-04 2013-10-10 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2016040182A1 (en) * 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) * 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP7307723B2 (ja) Ｐａｄ阻害剤としてのイミダゾ－ピリジン化合物
JP4954086B2 (ja) １ｈ−ピロロ［２，３−ｂ］ピリジン
TW202104189A (zh) 雙環化合物
AU2006232620A1 (en) Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
US20160289196A1 (en) PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
KR20060123208A (ko) 피라진 유도체 및 이의 약학적 용도
AU2007271008A1 (en) Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
JPWO2015099107A1 (ja) 含窒素６員環誘導体およびそれらを含有する医薬組成物
KR20190080951A (ko) 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도
JP2017534653A (ja) ブロモドメイン及びエキストラ末端タンパク質の阻害のための方法及び組成物
WO2015161745A1 (zh) 鬼臼毒素衍生物、其制备方法、药物组合物及应用
JP6353556B2 (ja) ナフチルアミド系化合物、その製造方法および使用
CA2689607A1 (en) Kinase inhibitor compounds
JP2020535196A (ja) Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
JP2017512796A (ja) 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用
WO2017088723A1 (zh) 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
KR20100019507A (ko) ７-알키닐-１,８-나프티리돈의 유도체, 그의 제조 방법 및 치료법에서의 그의 용도
WO2020108415A1 (zh) 一种trk激酶抑制剂化合物的中间体化合物及制备方法
CN108698990B (zh) 砜基取代的苯并杂环衍生物、其制法与医药上的用途
JP2003231633A (ja) 医薬組成物
WO2021121420A1 (zh) 苯并吡唑类化合物及其中间体、制备方法和应用
WO2021093172A1 (zh) Hbv抑制剂及其用途
CN111247143B (zh) 可用作蛋白激酶抑制剂的吡啶并喹唑啉衍生物
JP2009073743A (ja) 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物
WO2022012058A1 (zh) 稠环化合物及其中间体、制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20903967

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20903967

Country of ref document: EP

Kind code of ref document: A1